0001079973-17-000456.txt : 20170808 0001079973-17-000456.hdr.sgml : 20170808 20170808105418 ACCESSION NUMBER: 0001079973-17-000456 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170808 DATE AS OF CHANGE: 20170808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProtoKinetix, Inc. CENTRAL INDEX KEY: 0001128189 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943355026 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-32917 FILM NUMBER: 171013670 BUSINESS ADDRESS: STREET 1: 705 DUGAN ROAD CITY: BELPRE STATE: OH ZIP: 45714 BUSINESS PHONE: 304-299-5070 MAIL ADDRESS: STREET 1: 705 DUGAN ROAD CITY: BELPRE STATE: OH ZIP: 45714 FORMER COMPANY: FORMER CONFORMED NAME: RJV NETWORK INC DATE OF NAME CHANGE: 20010130 10-Q 1 pktx_10q-063017.htm FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2017

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to ___________________.

Commission file number:

PROTOKINETIX, INCORPORATED

(Exact name of registrant as specified in its charter)

Nevada		94-3355026
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

705 Dugan Road

Belpre, Ohio 45714

(Address of principal executive offices)

304-299-5070

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☐	(Do not check if a smaller reporting company)	Smaller reporting company ☒
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 8, 2017, there were 245,952,433 shares of ProtoKinetix, Incorporated that were issued and outstanding.

PROTOKINETIX, INCORPORATED

TABLE OF CONTENTS

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

Unaudited Condensed Balance Sheets	3

Unaudited Condensed Statements of Operations	4

Unaudited Condensed Statement of Stockholders’ Equity	5

Unaudited Condensed Statements of Cash Flows	6

Notes to Unaudited Condensed Financial Statements	7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3. Quantitative and Qualitative Disclosures About Market Risk	23

Item 4. Controls and Procedures	24

PART II

OTHER INFORMATION

Item 1. Legal Proceedings	25

Item 1A. Risk Factors	25

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 3. Defaults Upon Senior Securities	25

Item 4. Mine Safety Disclosure	25

Item 5. Other Information	25

Item 6. Exhibits	26

Signatures	27

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

BALANCE SHEETS

(Unaudited)


	June 30, 2017			December 31, 2016
ASSETS
Current Assets
Cash	$	238,277		$	371,029
Prepaid expenses and deposits (Notes 3 and 11)		142,500			70,384
Total current assets		380,777			441,413

Intangible assets (Note 4)		151,173			100,681

Total assets	$	531,950		$	542,094
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued liabilities (Note 10)	$	5,369		$	45,295
Total current liabilities		5,369			45,295
Stockholders' Equity
Common stock, $0.0000053 par value; 400,000,000 common shares authorized; 245,952,433 and 237,952,433 shares issued and outstanding as at June 30, 2017 and December 31, 2016 respectively (Note 9)		1,316			1,273
Additional paid-in capital		29,852,293			29,115,795
Accumulated deficit		(29,327,028	)		(28,620,269	)
Total stockholders’ equity		526,581			496,799
Total liabilities and stockholders’ equity	$	531,950		$	542,094

Basis of Presentation – Going Concern Uncertainties (Note 1)

Commitments and Contingency (Note 11)

See Notes to Financial Statements

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

STATEMENTS OF OPERATIONS

(Unaudited)

For the Three and Six Months Ended June 30, 2017 and 2016

	Three months ended June 30, 2017			Three months ended June 30, 2016			Six months ended June 30, 2017			Six months ended June 30, 2016



EXPENSES
Amortization – intangible assets (Note 4)	$	750		$	750		$	1,500		$	1,500
General and administrative		29,804			29,503			61,937			50,934
Professional fees (Note 10)		24,322			41,806			67,274			108,313
Research and development		86,235			108,481			155,273			180,132
Share-based compensation (Note 10)		186,025			190,244			416,541			374,763

		(327,136	)		(370,784	)		(702,525	)		(715,642	)


OTHER ITEM
Foreign exchange loss		(4,259	)		(2,169	)		(4,234	)		(2,166	)

Net loss for the period	$	(331,395	)	$	(372,953	)	$	(706,759	)	$	(717,808	)

Net loss per common share (basic and diluted)	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted average number of common shares outstanding (basic and diluted)		245,952,433			217,340,895			228,044,331			216,988,147

See Notes to Financial Statements

PROTOKINETIX, INCORPORATED

STATEMENT OF STOCKHOLDERS’ EQUITY

(Unaudited)

For the Period from December 31, 2016 to June 30, 2017

	Common Stock				Additional Paid-in		Accumulated
	Shares		Amount		capital		deficit			Total
Balance, December 31, 2016		237,952,433	$	1,273	$	29,115,795	$	(28,620,269	)	$	496,799

Issuance of common stock pursuant to private placement offering		8,000,000		43		319,957		-			320,000

Fair value of compensatory options issued		-		-		416,541		-			416,541

Net loss for the period		-		-		-		(706,759	)		(706,759	)

Balance, June 30, 2017		245,952,433	$	1,316	$	29,852,293	$	(29,327,028	)	$	526,581

See Notes to Financial Statements

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

STATEMENTS OF CASH FLOWS

(Unaudited)

For the Six Months Ended June 30, 2017 and 2016

	Six Months ended June 30, 2017			Six Months ended June 30, 2016

CASH FLOWS USED IN OPERATING ACTIVITIES
Net loss for the period	$	(706,759	)	$	(717,808	)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization – intangible assets		1,500			1,500
Issuance and amortization of common stock for services		-			7,000
Fair value of compensatory options granted		416,541			374,763

Changes in operating assets and liabilities:
Prepaid expenses and deposits		(87,730	)		(154,198	)
Accounts payable and accrued liabilities		(36,295	)		66,722

Net cash used in operating activities		(412,743	)		(422,021	)

CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of intangible assets		(40,009	)		(6,538	)

Net cash used in investing activities		(40,009	)		(6,538	)


CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock for cash		320,000			166,000

Net cash from financing activities		320,000			166,000

Net change in cash		(132,752	)		(262,559	)

Cash, beginning of period		371,029			371,072

Cash, end of period	$	238,277		$	108,513

Cash paid for interest	$	-		$	-

Cash paid for income taxes	$	-		$	-
Supplementary information – non-cash transactions:
Common stock issued for consulting services	$	-		$	7,000
Intangible asset costs previously included in accounts payable and accrued liabilities		3,631			-
Intangible asset costs previously included in prepaid expenses and deposits		15,614			-

See Notes to Financial Statements

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

Note 1. Basis of Presentation – Going Concern Uncertainties

ProtoKinetix, Incorporated (the "Company"), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999. The Company is a medical research company whose mission is the advancement of human health care.

The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins (“AFGP”) or anti-aging glycoproteins, trademarked AAGP™. During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $10,000 and 6,000,000 share purchase warrants with a fair value of $25,000 (Note 4).

During the year ended December 31, 2016, the Company filed Form 51-105F1 – Notice – OTC Issuer Ceases to be an OTC Reporting Issuer with the British Columbia Securities Commission (“BCSC”).

The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.

The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at June 30, 2017. These factors raise substantial doubt about the Company's ability to continue as a going concern.

The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective. Management is presently engaged in seeking additional working capital through equity financing or related party loans.

The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K, filed February 21, 2017, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

Note 2. Summary of Significant Accounting Policies (cont’d)

Use of Estimates

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.

Cash

Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.

Fair Value of Financial Instruments

Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.

The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Level 1 inputs are used to measure cash. At June 30, 2017 there were no other assets or liabilities subject to additional disclosure.

Income Taxes

The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

Note 2. Summary of Significant Accounting Policies (cont’d)

Intangible Assets – Patent and Patent Application Costs

The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.

As at June 30, 2017, the Company does not hold any intangible assets with indefinite lives.

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.

Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents, whereas no amortization has been recognized on the patent application costs as at June 30, 2017.

Research and Development Costs

Research and development costs are expensed as incurred.

Loss per Share and Potentially Dilutive Securities

Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 44,100,000 stock options (June 30, 2016 – 28,600,000), and 6,500,000 warrants (June 30, 2016 – 6,500,000) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.

Share-Based Compensation

The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

Note 2. Summary of Significant Accounting Policies (cont’d)

Share-Based Compensation (cont’d)

The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 “Stock-Based Transactions with Nonemployees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

Common stock

Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete.

Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

Related Party Transactions

A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

Recent Accounting Pronouncements

In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance did not have a material impact on the Company’s financial statements.

Accounting Standards Update 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy was effective for periods ending after December 16, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

Note 2. Summary of Significant Accounting Policies (cont’d)

Recent Accounting Pronouncements (cont’d)

Accounting Standards Update 2016-09 – Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect for periods ending after December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The adoption of this guidance did not have a material impact on the Company’s financial statements.

Accounting Standards Update 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements.

Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements.

Note 3. Prepaid Expenses and Deposits

The following summarizes the Company’s prepaid expenses and deposits outstanding as at June 30, 2017 and December 31, 2016:

	June 30, 2017		December 31, 2016

Deposit on research agreement (Note 11(c))	$	134,370	$	54,770
Other prepaid expenses		8,130		15,614

	$	142,500	$	70,384

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

Note 4. Intangible Assets

Intangible asset transactions are summarized as follows:

	Patent Rights		Patent Application Rights		Total
Cost
Balance, December 31, 2015	$	30,000	$	41,760	$	71,760
Additions		-		33,421		33,421
Balance, December 31, 2016	$	30,000	$	75,181	$	105,181
Additions		-		51,992		51,992
Balance, June 30, 2017	$	30,000	$	127,173	$	157,173

Accumulated amortization
Balance, December 31, 2015	$	1,500	$	-	$	1,500
Amortization		3,000		-		3,000
Balance, December 31, 2016	$	4,500	$	-	$	4,500
Amortization		1,500		-		1,500
Balance, June 30, 2017	$	6,000	$	-	$	6,000

Net carrying amounts
December 31, 2016	$	25,500	$	75,181	$	100,681
June 30, 2017	$	24,000	$	127,173	$	151,173

During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the “Patent Assignment”) with the Institut National des Sciences Appliquees de Rouen (“INSA”) for the assignment of certain patents and all rights associated therewith (the “Patents”). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $30,000 (25,000 Euros) (paid). During the six month period ended June 30, 2017, the Company recorded $1,500 (June 30, 2016 - $1,500) in amortization expense associated with the Patents.

During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the "Patent Application Rights"). In exchange for the Patent Application Rights, the Company agreed to pay $10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company has incurred $78,692 in direct costs relating to the Patent Application Rights, $40,922 of which were incurred during the six month period ended June 30, 2017.

The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

Note 4. Intangible Assets (cont’d)

During the year ended December 31, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells” (the “New Patent Application Rights”). In exchange for the New Patent Application Rights, the Company agreed to pay $1 (paid). The Company has incurred $13,481 in direct costs relating to the New Patent Application Rights, $11,065 of which were incurred during the six month period ended June 30, 2017.

No amortization was recorded on the Patent Application Rights to June 30, 2017.

Note 5. Credit Facility

On June 16, 2016, the Company executed a line of credit arrangement for an amount of up to $250,000 with Pleasants County Bank, West Virginia. Pursuant to the terms of the line of credit, interest will accrue on the amount of credit outstanding at a rate of 1.5% above the prime rate adjusted monthly. The Company’s President and CEO pledged personal assets to secure the line of credit and the Company pledged its patent rights in the provisional patent application numbered 62287857, dated January 21, 2016, “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells”. As at March 31, 2017 and December 31, 2016, the balance outstanding was $nil. As of June 30, 2017 the line of credit was canceled and the pledged assets were released.

Note 6. Common Shares Issued for Services

During the six month periods ended June 30, 2017 and 2016, the Company issued shares of common stock for services and other value rendered as follows:

2017	Number of Shares		Value per Share		Total

January - June 2017		-	$	-	$	-
		-			$	-

2016	Number of Shares		Value per Share		Total

March 2016		100,000	$	0.07	$	7,000
		100,000			$	7,000

Note 7. Stock Options

On December 30, 2016, the Board of Directors of the Company adopted the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”). The Board of Directors adopted the 2017 Plan as it anticipates utilizing equity compensation as part of its ongoing standard corporate operations and in connection with its contemplated activities going forward.

The aggregate number of shares that may be issued under the 2017 Plan is 30,000,000 shares subject to adjustment as provided therein. The 2017 Plan includes two types of options. Options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended are referred to as incentive options. Options which are not intended to qualify as incentive options are referred to as non-qualified options.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

Note 7. Stock Options (cont’d)

As of June 30, 2017, 16,200,000 options and no shares of common stock have been granted under the 2017 Plan.

The 2017 Plan is administered by the Board of Directors, or a committee appointed by the Board of Directors. In addition to determining who will be granted options or stock bonuses, the committee has the authority and discretion to determine when options and bonuses will be granted and the number of options and bonuses to be granted. The committee also may determine a vesting and/or forfeiture schedule for bonuses and/or options granted, the time or times when each option becomes exercisable, the duration of the exercise period for options and the form or forms of the agreements, certificates or other instruments evidencing grants made under the 2017 Plan. The committee may determine the purchase price of the shares of common stock covered by each option. The committee also may impose additional conditions or restrictions not inconsistent with the provisions of the 2017 Plan. The committee may adopt, amend and rescind such rules and regulations as in its opinion may be advisable for the administration of the 2017 Plan.

In the event that a change, such as a stock split, is made in the Company’s capitalization which results in an exchange or other adjustment of each share of common stock for or into a greater or lesser number of shares, appropriate adjustments will be made to unvested bonuses and in the exercise price and in the number of shares subject to each outstanding option. The committee also may make provisions for adjusting the number of bonuses or underlying outstanding options in the event the Company effects one or more reorganizations, recapitalizations, rights offerings, or other increases or reductions of shares of its outstanding common stock. Options and bonuses may provide that in the event of the dissolution or liquidation of the Company, a corporate separation or division or the merger or consolidation of the Company, the holder may exercise the option on such terms as it may have been exercised immediately prior to such dissolution, corporate separation or division or merger or consolidation; or in the alternative, the committee may provide that each option granted under the 2017 Plan shall terminate as of a date fixed by the committee.

The exercise price of any option granted under the 2017 Plan must be no less than 100% of the “fair market value” of the Company’s common stock on the date of grant. The exercise period of any option shall not exceed ten years from the date of grant of the option. Any incentive stock option granted under the 2017 Plan to a person owning more than 10% of the total combined voting power of the common stock must be at a price of no less than 110% of the fair market value per share on the date of grant and the term shall be for no more than five years.

Stock option transactions are summarized as follows:

	Number of Stock Options			Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Life
				$		$		(Years)
Outstanding, December 31, 2016		28,900,000			0.06		0.04
Options granted		16,200,000			0.05		0.06
Options expired		(1,000,000	)		0.10		0.03
Outstanding, June 30, 2017		44,100,000			0.06		0.05	2.72

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

Note 7. Stock Options (cont’d)

The fair values of the stock options granted during the six month periods ended June 30, 2017 and 2016 were estimated using the Black-Scholes Option Pricing Model. The weighted average assumptions used in the pricing model for these options are as follows:

	June 30, 2017			June 30, 2016
Risk-free interest rate		1.05	%		0.56	%
Dividend yield		0.00	%		0.00	%
Expected stock price volatility		125.00	%		125.00	%
Expected forfeiture rate		0.00	%		0.00	%
Expected life	3.46 years			3.94 years

The following non-qualified stock options were outstanding and exercisable at June 30, 2017:

Expiry date	Exercise Price		Number of Options Outstanding		Number of Options Exercisable
					$
February 25, 2020		0.04		2,000,000		-
February 24, 2018		0.05		1,000,000		1,000,000
February 25, 2020		0.04		4,000,000		4,000,000
February 28, 2020		0.04		5,000,000		5,000,000
June 30, 2018		0.10		600,000		600,000
December 31, 2019		0.08		15,000,000		15,000,000
October 05, 2018		0.08		300,000		300,000
December 31, 2020		0.05		16,200,000		8,100,000
				44,100,000		34,000,000

As at June 30, 2017, the aggregate intrinsic value of the Company’s stock options is $674,000 (December 31, 2016 – $110,000). The weighted average fair value of stock options granted during the six month period ended June 30, 2017 is $0.06 (2016 - $0.05).

Note 8. Warrants

Warrant transactions for the six month period ended June 30, 2017 are summarized as follows:

		Number of Warrants				Weighted Average Exercise Price
Balance, December 31, 2016 and June 30, 2017			6,500,000			$	0.11

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

Note 8. Warrants (cont’d)

The following warrants were outstanding and exercisable as at June 30, 2017:

Number of Warrants		Exercise Price ($)		Expiry Date
	500,000		0.25	November 8, 2018
	6,000,000		0.10	April 22, 2020
	6,500,000

Note 9. Stockholders’ Equity

The Company is authorized to issue 400,000,000 (December 31, 2016 – 400,000,000) shares of $0.0000053 par value common stock. Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of June 30, 2017 (December 31, 2016 - $nil).

During the six month period ended June 30, 2017, the Company:

a)	Issued 8,000,000 shares of common stock to investors (which included both the President and CEO as well as the CFO of the Company) at $0.04 for gross proceeds of $320,000.

Note 10. Related Party Transactions and Balances

During the six month period ended June 30, 2016, the Company:

Entered into a consulting agreement with an effective date of January 1, 2016 with the Company’s President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Company’s President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control. In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of an Application Sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement. Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options are fully vested as at June 30, 2017.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

Note 10. Related Party Transactions and Balances (cont’d)

Entered into a consulting agreement with an effective date of January 1, 2016 with the Company’s CFO whereby she will be compensated at a monthly fee of $6,000 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Company’s CFO $36,000 if terminated without cause or $72,000 upon termination due to a change of control event. Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options are fully vested as at June 30, 2017. A total of $36,000 was paid to the Company’s CFO during the period ended June 30, 2016.

Entered into a directorship agreement with an effective date of January 1, 2016 with a director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options are fully vested as at June 30, 2017.

d)	Recognized $271,850 in share-based compensation associated with stock options granted to key management personnel.

During the six months ended June 30, 2017, the Company:

Entered into a consulting agreement with an effective date of January 1, 2017 with the Company’s President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2017. The agreement also stipulates a termination fee that would pay the Company’s President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control. In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of a sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement. Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note7). The options vest in equal instalments on a quarterly basis beginning March 31, 2017.

Entered into a consulting agreement with an effective date of January 1, 2017 with the Company’s CFO whereby she will be compensated at a monthly fee of $6,000 for services through to December 31, 2017. The agreement also stipulates a termination fee that would pay the Company’s CFO $72,000 per year of service (including the pro-rata amount for partial years of service) if terminated without cause or upon termination due to a change of control event. Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7). The options vest in equal instalments on a quarterly basis beginning March 31, 2017. A total of $36,000 was paid to the Company’s CFO during the period ended June 30, 2017.

Entered into a directorship agreement with an effective date of January 1, 2017 with a director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7). The options vest in equal instalments on a quarterly basis beginning March 31, 2017.

d)	Recognized $198,274 in share-based compensation associated with stock options granted to key management personnel.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

Note 10. Related Party Transactions and Balances (cont’d)

As at June 30, 2017 and December 31, 2016, the following amounts are due to related parties:

			June 30, 2017				December 31, 2016
Clarence Smith (CEO)	Accounts payable and accrued liabilities		$	-			$	81

Amounts included in accounts payable and accrued liabilities are non-interest bearing, unsecured and repayable on demand.

Note 11. Commitments and Contingency

As at June 30, 2017, the Company has the following commitments:

Entered into a consulting agreement with an effective date of January 1, 2017 whereby the Company would pay the consultant $7,000 per month for providing research and development services. Pursuant to the agreement, the consultant was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7). The options vest in equal instalments on a quarterly basis beginning March 31, 2017.

Entered into a consulting agreement for business development services effective January 1, 2017. The consultant was granted 1,200,000 stock options exercisable into common shares of the Company at a price of $0.05 per share until December 31, 2020 (Note 7). The options vest in equal instalments on a quarterly basis beginning March 31, 2017.

Entered into a Collaborative Research Agreement (the “CREA”) effective May 31, 2016 with The University of British Columbia (“UBC”) for a term of 2 years. Pursuant to the CREA, the Company paid a total of CAD $169,000 ($131,448) in advance for services to be provided by UBC in the first year, and paid an additional CAD $201,500 ($146,585) during the six month period ended June 30, 2017, in advance of services to be provided by UBC in the second year. The CREA can be terminated by either party with 30 days’ written notice. As at June 30, 2017, a total of $134,370 is included in prepaid expenses and deposits (December 31, 2016 - $54,770).

Entered into a consulting agreement effective March 1, 2015, whereby the Company would pay the consultant $2,700 per month for an initial term of 1 year, continued on a year-to-year basis thereafter unless otherwise terminated by either party with at least 30 days’ notice, for providing public relations services. The consultant is also entitled to 400,000 shares of common stock, which will be issued at a rate of 25% (100,000 shares) every 3 months over the term of the agreement (200,000 shares issued during the six month period ended June 30, 2016 (Note 6)). The consultant was also issued 1,000,000 stock options on signing during the year ended December 31, 2015, with each stock option exercisable into a common share at a price of $0.10. The stock options expired March 12, 2016.

PROTOKINETIX, INCORPORATED

(A Developmental Stage Company)

NOTES TO THE FINANCIAL STATEMENTS

June 30, 2017

Note 11. Commitments and Contingency (cont’d)

Entered into a royalty agreement with the Governors of the University of Alberta (the “University”) whereby the University had developed certain intellectual property (the “Additional Patent Rights”) in conjunction with and by permission of the Company employing patented intellectual property of the Company. The agreement assigns the Additional Patent Rights to the Company in return for 5% of any future gross revenues (the “Royalty”) derived from products arising from the Patent Rights. The Company will have the right and option for two years from the earlier of September 1, 2015 or the first date that the University publishes its research related to the Additional Patent Rights to buy out all of the University’s Royalty for consideration of the aggregate sum of CAD $5,000,000.

Entered into a consulting agreement effective May 1, 2015, whereby the Company would pay the consultant $4,000 per month for an initial term of 1 year, continued on a year-to-year basis thereafter unless otherwise terminated by either party with at least 30 days’ notice for providing research and development services. During the six month period ended June 30, 2017 the contract was revised whereby the Company would pay the consultant CAD $4,000 per month retroactively beginning January 1, 2017. As a result of the revision, an amount of $8,130 is included within prepaid expenses as at June 30, 2017 and will be applied towards future services.

g)	Entered into a Material Transfer Agreement effective March 31, 2017 with Proactive Immune Sciences Corporation (“Proactive”) for a term of 1 year. The Company will furnish AAGP™ at no cost to Proactive so that they may test and evaluate AAGP™ for possible use in Immune Cell Banking.

The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, “Report of Foreign Bank and Financial Accounts” (“FBARs”). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs. Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no underreported tax liabilities. The Company may be liable for civil penalties for certain tax years in an indeterminate amount for not complying with the FBAR reporting and recordkeeping requirements. No claim has been asserted by the U.S. Internal Revenue Service; before any claim is expressly asserted the Company intends to cooperate with the Internal Revenue Service to minimize any liability. The Company is unable to determine the amount of any penalties that may be assessed at this time.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless the context requires otherwise, references in this document to “ProtoKinetix”, “we”, “our”, “us” or the “Company” are to ProtoKinetix, Incorporated.

The following discussion provides information regarding the results of operations for the six month period ended June 30, 2017 and 2016, and our financial condition, liquidity and capital resources as of June 30, 2017, and December 31, 2016. The financial statements and the notes thereto contain detailed information that should be referred to in conjunction with this discussion.

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this Quarterly Report on Form 10-Q include “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements, other than statements of historical facts, included herein and therein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” “will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases. Although we believe that the expectations reflected in these forward looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not considered to be) guarantees of future performance. Our results could differ materially from those anticipated in these forward looking statements as a result of certain factors, including, among others:

•

Our capital requirements and the uncertainty of being able to obtain additional funding on terms acceptable to us;

•

Our plans to develop and commercialize products from the AAGP™ molecule;

•

Ongoing testing of the AAGP™ molecule;

•

Our intellectual property position;

•

Our commercialization, marketing and manufacturing capabilities and strategy;

•

Our ability to retain key members of our senior management and key scientific consultants;

•

The effects of competition;

•

Our potential tax liabilities resulting from conducting business in the United States and Canada;

•

The effect of further sales or issuances of our common stock and the price and volume volatility of our common stock; and

•

Our common stock’s limited trading history.

Finally, our future results will depend upon various other risks and uncertainties, including, but not limited to, those detailed in our filings with the SEC under the Exchange Act and the Securities Act, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. All forward looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph and elsewhere in this Quarterly Report. Other than as required under securities laws, we do not assume a duty to update these forward looking statements, whether as a result of new information, subsequent events or circumstances, changes in expectations or otherwise.

Business Overview

ProtoKinetix, Incorporated is a research and development stage bio-technology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins, trademarked as AAGPs™. The Company has recently been in the process of directing major efforts to the practical side of commercial validation. The commercial applications for AAGPs™ in large markets such as targeted health care solutions are numerous, and ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP™ to market.

Results of Operations

The following table shows selected financial data and operating results for the periods noted. Following the table, please see management’s discussion of significant changes.

	For the Six Months Ended
	June 30,
	2017			2016
Revenues	$	-		$	-
Cost of Sales		-			-
Gross (Loss) Profit		-			-
Operating Expenses
Amortization-Intangible Assets	$	1,500		$	1,500
General and Administrative		61,937			50,934
Professional Fees		67,274			66,507
Research and Development		155,273			180,132
Share-Based Compensation		416,541			374,763
Total Operating Expenses		702,525			715,642
Loss from Operations		(702,525	)		(715,642	)

Other Income
Foreign Exchange Loss		(4,234	)		(2,166	)
Total Other Income		(4,234	)		(2,166	)
Net Loss	$	(706,759	)		(717,808	)

Revenues

We had no revenues for the six month periods ended June 30, 2017 and 2016.

Gross Profit and Expenses

The Company’s net loss was $706,759 for the six month period ended June 30, 2017 compared to $717,808 for the six month period ended June 30, 2016. These expenses were primarily incurred for professional fees, consulting services related to the operations of the Company’s business, research and development and other general and administrative expenses. Significant changes from the prior six month period ended June 30, 2016 include:

General and administrative expenses increased by $11,003 from $50,934 to $61,937 primarily as a result of an increase in advertising and promotion as well as an increase in travel expenses associated with the commencement of clinical trials.

Professional fees increased by $767 from $66,507 to $67,274 primarily as a result of a slight increase in legal fees associated with company operations.

Research and development decreased by $24,859 from $180,132 to $155,273 primarily as a result of completion of needed testing for inclusion in the Investigational Testing Authorization Application to Health Canada by the Governors of the University of Alberta.

Share-based compensation increased by $41,778 from $374,763 to $416,541 primarily as a result of an increase in stock option valuation for the current quarter.

Liquidity and Capital Resources

The following summarizes our statements of cash flows at June 30, 2017 and December 31, 2016:

	June 30, 2017		December 31, 2016

Cash	$	238,277	$	371,029

Working Capital	$	375,408	$	396,118

At June 30, 2017, we had $238,277 in cash and $380,777 in total current assets. As of June 30, 2017 we had a working capital position of $375,408. Based upon our working capital equity as of June 30, 2017, we require additional equity and/or debt financing in order to meet cash flow projections and carry forward our business objectives. There can be no assurance that in the future we will be able to raise capital from outside sources in sufficient amounts to fund our new business.

The failure to secure adequate outside funding would have an adverse effect on our plan of operation and results therefrom and a corresponding negative impact on stockholder liquidity.

Sources and Uses of Cash

Net Cash Used in Operating Activities

Net cash used in operating activities decreased by $9,278 from $422,021 to $412,743 for the six months ended June 30, 2016 and 2017, respectively. This decrease was predominantly due to a decrease in payments made to the Company’s vendors.

Net Cash Used in Investing Activities

Net cash used in investing activities was $40,009 for the six month period ended June 30, 2017 while the Company had net cash used in investing activities of $6,538 for the comparative period. The difference is attributable to an increase in the purchase of intangible assets.

Net Cash Provided by Financing Activities

Net cash provided by financing activities increased by $154,000 from $166,000 to $320,000 for the six months ended June 30, 2016 and 2017, respectively due to an increase in private placements.

Going Concern

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), which contemplate continuation of the Company as a going concern. The history of losses and the inability for the Company to make a profit from selling a good or service has raised substantial doubt about our ability to continue as a going concern. In spite of the fact that the current cash obligations of the Company are relatively minimal, given the cash position of the Company, we have very little cash to operate. We intend to fund the Company and attempt to meet corporate obligations by selling common stock. However, the Company’s common stock is at a low price and is not actively traded.

Off-Balance Sheet Arrangements

None.

Contractual Obligations

As a smaller reporting company, we are not required to provide the information required by paragraph (a)(5) of this Item.

Critical Accounting Policies

The preparation of financial statements in conformity with U.S. GAAP requires management to make a variety of estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and (ii) the reported amounts of revenues and expenses during the reporting periods covered by the financial statements.

Our management routinely makes judgments and estimates about the effect of matters that are inherently uncertain. As the number of variables and assumptions affecting the future resolution of the uncertainties increase, these judgments become even more subjective and complex. Although we believe that our estimates and assumptions are reasonable, actual results may differ significantly from these estimates. Changes in estimates and assumptions based upon actual results may have a material impact on our results of operation and/or financial condition. Our significant accounting policies are disclosed in Note 2 to the Financial Statements included in this Form 10-Q.

While all of the significant accounting policies are important to the Company’s financial statements, the following accounting policies and the estimates derived there from have been identified as being critical.

Share-Based Compensation

On July 1, 2015, the Board of Directors of the Company adopted the 2015 Stock Option and Stock Bonus Plan (the “Plan”). The Company has granted warrants and options to purchase shares of the Company’s common stock to various parties for consulting services outside of the Plan, and beginning July 1, 2015 and ending December 31, 2016 pursuant to the Plan. On December 30, 2016, the Board of Directors of the Company adopted the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”). During the six month period ended June 30, 2017, the Company granted options pursuant to the 2017 Plan. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

Sales and Marketing

The Company is currently not selling or marketing any products.

Inflation

Although management expects that our operations will be influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the six months ended June 30, 2017.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

Item 4: Controls and Procedures

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 (the “1934 Act”) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the 1934 Act is accumulated and communicated to management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, under the direction of our Chief Executive Officer (who is our principal executive officer), and Chief Financial Officer (who is our principal accounting officer) has evaluated the effectiveness of our disclosure controls and procedures as required by 1934 Act Rule 13a-15(b) as of June 30, 2017 (the end of the period covered by this report). Based on that evaluation, our principal executive officer and our principal accounting officer concluded that these disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosure and are effective to provide reasonable assurance that such information is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

The Company, including its Chief Executive Officer and Chief Financial Officer, does not expect that its internal controls and procedures will prevent or detect all error and all fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) promulgated by the SEC under the 1934 Act) during the six months ended June 30, 2017, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Other than reported in the Company’s Quarterly Report on Form 10-Q for the six month period ended June 30, 2017, the Company and its management are not aware of any regulatory or legal proceedings or investigations pending involving the Company, any of its subsidiaries or affiliates, or any of their respective officers, directors or employees.

Item 1A. Risk Factors

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. However, our current risk factors are set forth in our Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on February 21, 2017, and such risk factors are incorporated herein by this reference.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Other than previously reported, there have been no unregistered sales of equity securities during the six month period ended June 30, 2017.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosure

Not applicable.

Item 5. Other Information

Effective June 30, 2017, the Company into a Material Transfer Agreement with Proactive Immune Sciences Corporation (“Proactive”) for a term of one year. The Company will furnish AAGP™ at no cost to Proactive so that they may test and evaluate AAGP™ for possible use in Immune Cell Banking.

Item 6. Exhibits

The following is a complete list of exhibits filed as part of this Form 10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K.

EXHIBIT INDEX

The following documents are being filed with the Commission as exhibits to this Quarterly Report on Form 10-Q.

Exhibit		Description
3.1		Certificate of Incorporation¹
3.2		Bylaws¹
4.1		2015 Stock Option and Stock Bonus Plan²
4.2		2017 Stock Option and Stock Bonus Plan⁷
10.1		Assignment of Patents and Patent Application between the Company and Institut National des Sciences Appliquées de Rouen dated January 5, 2015³
10.2		Settlement and Indemnity Agreement by and between the Company and Standard Bankcorp Inc. and Mark Ralston dated March 2, 2015³
10.3		Royalty Agreement between the Company and The Governors of the University of Alberta, dated April 8, 2015³
10.4		Technology Transfer Agreement between the Company and Grant Young, dated April 22, 2015⁴
10.5		ITR Master Contract between the Company and ITR Laboratories Canada Inc., dated April 19, 2016⁸
10.6		Universal Agreement between the Company and Grant Young, dated May 20, 2016⁹
10.7		Collaborative Research Agreement between the Company and the University of British Columbia, dated May 31, 2016⁹
10.8		Consulting Agreement between the Company and Clarence E. Smith, dated December 30, 2016⁷
10.9		Consulting Agreement between the Company and Susan M. Woodward, dated December 30, 2016⁷
10.10		Director Consulting Agreement between the Company and Edward P. McDonough, dated December 30, 2016⁷
14.1		Code of Ethics⁶
31.1		Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002^*
31.2		Certification of the Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002^*
32.1		Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002^**
32.2		Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002^**
101.INS		XBRL Instance Document
101.SCH		XBRL Schema Document
101.CAL		XBRL Calculation Linkbase Document
101.DEF		XBRL Definition Linkbase Document
101.LAB		XBRL Label Linkbase Document
101.PRE		XBRL Presentation Linkbase Document

	1.	Incorporated by reference from the Company’s registration statement on Form 10-SB filed on June 22, 2001 with the SEC.
	2.	Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on August 14, 2015 with the SEC.
	3.	Incorporated by reference from the Company’s Annual Report on Form 10-K filed on April 14, 2015 with the SEC.
	4.	Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on May 20, 2015 with the SEC.
	5.	Incorporated by reference from the Company’s Annual Report on Form 10-K filed on March 30, 2016 with the SEC.
	6.	Incorporated by reference from the Company’s Annual Report on Form 10-K filed on April 13, 2006 with the SEC.
	7.	Incorporated by reference from the Company’s Annual Report on Form 10-K filed on February 21, 2017 with the SEC.
	8.	Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on May 16, 2016 with the SEC.
	9.	Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on August 15, 2016 with the SEC.
	*.	Filed herewith.
	**	Furnished, not filed herewith.

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 8, 2017		PROTOKINETIX, INCORPORATED

		By: /s/ Clarence E. Smith
		Clarence E. Smith
		Chief Executive Officer

		By: /s/ Susan M. Woodward
		Susan M. Woodward
		Chief Financial Officer

EX-31.1 2 ex31x1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Clarence E. Smith, certify that:

I have reviewed this Quarterly Report on Form 10-Q of ProtoKinetix, Incorporated for the period ended June 30, 2017;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

August 8, 2017	/s/ Clarence E. Smith
	Name:	Clarence E. Smith
	Title:	Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 ex31x2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Susan M. Woodward, certify that:

I have reviewed this Quarterly Report on Form 10-Q of ProtoKinetix, Incorporated for the period ended June 30, 2017;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

August 8, 2017	/s/ Susan M. Woodward
	Name:	Susan M. Woodward
	Title:	Chief Financial Officer (Principal Financial Officer)

EX-32 4 ex32.htm EXHIBIT 32

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of ProtoKinetix, Incorporated, (the “Company”) on Form 10-Q for the period ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Clarence E. Smith, Chief Executive Officer and Principal Executive Officer of the Company of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigned’s knowledge and belief:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

August 8, 2017	/s/ Clarence E. Smith
	Name:	Clarence E. Smith
	Title:	Chairman of the Board and Chief Executive Officer (Principal Executive Officer)

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

EX-32.2 5 ex32x2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of ProtoKinetix, Incorporated, (the “Company”) on Form 10-Q for the period ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Susan M. Woodward, Chief Financial Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigned’s knowledge and belief:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

August 8, 2017	/s/ Susan M. Woodward
	Name:	Susan M. Woodward
	Title:	Chief Financial Officer (Principal Financial Officer)

EX-101.INS 6 pktx-20170630.xml XBRL INSTANCE DOCUMENT 0001128189 2017-01-01 2017-06-30 0001128189 2017-03-31 0001128189 2016-12-31 0001128189 2015-12-31 0001128189 us-gaap:PatentsMember pktx:CostMember 2016-12-31 0001128189 pktx:PatentApplicationRightsMember pktx:CostMember 2016-12-31 0001128189 pktx:TotalMember pktx:CostMember 2016-12-31 0001128189 us-gaap:PatentsMember pktx:AccumulatedAmortizationMember 2016-12-31 0001128189 pktx:PatentApplicationRightsMember pktx:AccumulatedAmortizationMember 2016-12-31 0001128189 pktx:TotalMember pktx:AccumulatedAmortizationMember 2016-12-31 0001128189 pktx:TotalMember pktx:CostMember 2015-12-31 0001128189 pktx:TotalMember pktx:AccumulatedAmortizationMember 2015-12-31 0001128189 us-gaap:PatentsMember pktx:NetCarryingAmountMember 2016-12-31 0001128189 pktx:PatentApplicationRightsMember pktx:NetCarryingAmountMember 2016-12-31 0001128189 pktx:TotalMember pktx:NetCarryingAmountMember 2016-12-31 0001128189 pktx:ClarenceSmithCEOMember 2016-12-31 0001128189 us-gaap:CommonStockMember 2016-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001128189 us-gaap:RetainedEarningsMember 2016-12-31 0001128189 2016-01-01 2016-03-31 0001128189 us-gaap:WarrantMember 2016-01-01 2016-03-31 0001128189 us-gaap:StockOptionMember 2016-01-01 2016-03-31 0001128189 us-gaap:PatentsMember pktx:CostMember 2016-01-01 2016-12-31 0001128189 pktx:PatentApplicationRightsMember pktx:CostMember 2016-01-01 2016-12-31 0001128189 pktx:TotalMember pktx:CostMember 2016-01-01 2016-12-31 0001128189 us-gaap:PatentsMember pktx:AccumulatedAmortizationMember 2016-01-01 2016-12-31 0001128189 pktx:PatentApplicationRightsMember pktx:AccumulatedAmortizationMember 2016-01-01 2016-12-31 0001128189 pktx:TotalMember pktx:AccumulatedAmortizationMember 2016-01-01 2016-12-31 0001128189 pktx:MarchMember 2016-01-01 2016-03-31 0001128189 pktx:JanuaryMarchMember 2016-01-01 2016-03-31 0001128189 us-gaap:StockOptionMember 2016-12-31 0001128189 us-gaap:StockOptionMember 2017-01-01 2017-06-30 0001128189 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001128189 2017-06-30 0001128189 us-gaap:PatentsMember pktx:CostMember 2017-01-01 2017-06-30 0001128189 pktx:PatentApplicationRightsMember pktx:CostMember 2017-01-01 2017-06-30 0001128189 pktx:TotalMember pktx:CostMember 2017-01-01 2017-06-30 0001128189 pktx:TotalMember pktx:CostMember 2017-06-30 0001128189 pktx:PatentApplicationRightsMember pktx:CostMember 2017-06-30 0001128189 us-gaap:PatentsMember pktx:CostMember 2017-06-30 0001128189 pktx:PatentApplicationRightsMember pktx:AccumulatedAmortizationMember 2017-01-01 2017-06-30 0001128189 us-gaap:PatentsMember pktx:AccumulatedAmortizationMember 2017-01-01 2017-06-30 0001128189 pktx:TotalMember pktx:AccumulatedAmortizationMember 2017-01-01 2017-06-30 0001128189 us-gaap:PatentsMember pktx:AccumulatedAmortizationMember 2017-06-30 0001128189 pktx:PatentApplicationRightsMember pktx:AccumulatedAmortizationMember 2017-06-30 0001128189 pktx:TotalMember pktx:AccumulatedAmortizationMember 2017-06-30 0001128189 us-gaap:PatentsMember pktx:NetCarryingAmountMember 2017-06-30 0001128189 pktx:PatentApplicationRightsMember pktx:NetCarryingAmountMember 2017-06-30 0001128189 pktx:TotalMember pktx:NetCarryingAmountMember 2017-06-30 0001128189 us-gaap:StockOptionMember 2017-06-30 0001128189 us-gaap:StockOptionMember 2016-01-01 2016-06-30 0001128189 pktx:Date3Member 2017-06-30 0001128189 pktx:Date2Member 2017-06-30 0001128189 pktx:Date4Member 2017-06-30 0001128189 pktx:Date12Member 2017-06-30 0001128189 pktx:Date9Member 2017-06-30 0001128189 pktx:Date11Member 2017-06-30 0001128189 pktx:Date6Member 2017-06-30 0001128189 2016-01-01 2016-06-30 0001128189 us-gaap:OptionMember 2017-06-30 0001128189 us-gaap:CommonStockMember 2017-06-30 0001128189 pktx:WarrantOneMember 2017-06-30 0001128189 pktx:WarrantTwoMember 2017-06-30 0001128189 pktx:WarrantTwoMember 2017-01-01 2017-06-30 0001128189 pktx:WarrantOneMember 2017-01-01 2017-06-30 0001128189 pktx:ClarenceSmithCEOMember 2017-06-30 0001128189 2016-04-01 2016-06-30 0001128189 2017-04-01 2017-06-30 0001128189 2017-08-08 0001128189 us-gaap:CommonStockMember 2017-01-01 2017-06-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-06-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001128189 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0001128189 us-gaap:RetainedEarningsMember 2017-06-30 0001128189 2016-06-30 0001128189 pktx:Date1Member 2017-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure --12-31 pktx 2017-06-30 No Smaller Reporting Company No 10-Q false 2017 ProtoKinetix, Inc. 0001128189 Yes Q2

0.0000053

400000000

441413

380777

100681

30000

75181

105181

4500

71760

1500

25500

75181

100681

151173

157173

127173

30000

6000

24000

127173

151173

542094

531950

45295

5369

45295

5369

542094

531950

496799

1273

29115795

-28620269

526581

1316

29852293

-29327028

-28620269

-29327028

29115795

29852293

1273

1316

237952433

245952433

237952433

245952433

1500

3000

1500

750

-706759

-717808

-372953

-331395

-706759

320000

319957

416541 416541

ProtoKinetix, Incorporated (the "Company"), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999.  The Company is a medical research company whose mission is the advancement of human health care.   The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins (AFGP) or anti-aging glycoproteins, trademarked AAGP.  During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $10,000 and 6,000,000 share purchase warrants with a fair value of $25,000 (Note 4).   During the year ended December 31, 2016, the Company filed Form 51-105F1 Notice OTC Issuer Ceases to be an OTC Reporting Issuer with the British Columbia Securities Commission (BCSC).   The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.   The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at June 30, 2017.  These factors raise substantial doubt about the Company's ability to continue as a going concern.   The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities.  Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective.  Management is presently engaged in seeking additional working capital through equity financing or related party loans.   The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

Warrant transactions for the six month period ended June 30, 2017 are summarized as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> Number of Warrants</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: justify">Balance, December 31, 2016 and June 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">6,500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">0.11</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   The following warrants were outstanding and exercisable as at June 30, 2017:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; text-indent: 21pt">Number of Warrants</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price ($)</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid">   Expiry Date</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 30%; text-align: right">500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 31%; text-align: right">0.25</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: top; width: 34%; text-align: right">November 8, 2018</td></tr> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">6,000,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">0.10</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right">April 22, 2020</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: top; border-bottom: black 2.25pt double"> </td></tr> </table>   The following summarizes the Companys prepaid expenses and deposits outstanding as at June 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid"> June 30, 2017</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid"> December 31, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td colspan="2" style="vertical-align: top; font-weight: bold"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td colspan="2" style="vertical-align: top; font-weight: bold"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 68%; font-weight: bold; text-align: justify">Deposit on research agreement (Note 11(c))</td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold">$</td> <td style="vertical-align: bottom; width: 13%; font-weight: bold; text-align: right">134,370</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold">$</td> <td style="vertical-align: bottom; width: 13%; font-weight: bold; text-align: right">54,770</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Other prepaid expenses</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: right">8,130</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">15,614</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">142,500</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">70,384</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">   2017</td> <td style="border-bottom: black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">Value per Share</td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">Total</td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td colspan="2" style="vertical-align: top; font-weight: bold"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 49%; font-weight: bold; text-align: justify">January - June 2017</td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 14%; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold">$</td> <td style="vertical-align: bottom; width: 14%; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold">$</td> <td style="vertical-align: bottom; width: 14%; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 2.2pt; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">   2016</td> <td style="border-bottom: black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">Value per Share</td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">Total</td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td colspan="2" style="vertical-align: top; font-weight: bold"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 49%; font-weight: bold; text-align: justify">March 2016</td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 14%; font-weight: bold; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold">$</td> <td style="vertical-align: bottom; width: 14%; font-weight: bold; text-align: right">0.07</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold">$</td> <td style="vertical-align: bottom; width: 14%; font-weight: bold; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 2.2pt; font-weight: bold; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2.2pt; font-weight: bold"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr> <td style="vertical-align: top; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td style="vertical-align: top; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1pt solid; font-weight: bold; text-align: center">June 30,2017</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1pt solid; font-weight: bold; text-align: center">December 31, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">Clarence Smith (CEO)</td> <td style="vertical-align: top; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">Accounts payable and accrued liabilities</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">-</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">81</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td></tr> <tr> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td></tr> </table>

6500000

28600000

44100000

6500000

54770

134370

15614

8130

33421

51992

250000

7000

100000

.07 0

7000

28900000

44100000

4000000

1000000

5000000

16200000

15000000

300000

2000000

600000

0.06

0.11

0.06

0.04

0.05

0.04

0.05

0.08

0.04

0.10

.06

0.06

0.05

0.0105

0.0056

0.00

1.25

0.00 0.00

P3Y5M8D

P3Y11M12D

34000000

4000000

1000000

5000000

8100000

15000000

300000

600000

6500000

500000

6000000

0.25 0.10 April 22, 2020 November 8, 2018

36000

16200000

110000

674000

6500000

245952433

16200000

1000000

0.05

0.10

0.04

0.05

0.03

P2Y8M19D

134370 154595

8130

70384

142500

702525

715642

370784

327136

416541

374763

190244

186025

155273

180132

108481

86235

67274

108313

41806

24322

61937

50934

29503

29804

228044331

216988147

217340895

245952433

-0.00

0.00

-0.00

-4234

-2166

-2169

-4259

371029

371072

238277

108513

-132752

-262559

320000

166000

-40009

-6538

40009

6538

-412743

-422021

-36295

66722

87730

154198

416541 374763 7000

320000

166000

15614 3631 7000

Basis of Presentation   The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (US GAAP) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Companys audited financial statements and notes thereto for the year ended December 31, 2016, included in the Companys Annual Report on Form 10-K, filed February 21, 2017, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.   Use of Estimates   Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.   Cash   Cash consists of funds held in checking accounts.  Cash balances may exceed federally insured limits from time to time.   Fair Value of Financial Instruments   Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.   The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 Fair Value Measurements and Disclosures which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:   Level 1 quoted prices in active markets for identical assets or liabilities Level 2 quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 inputs that are unobservable (for example cash flow modeling inputs based on assumptions)   Level 1 inputs are used to measure cash. At June 30, 2017 there were no other assets or liabilities subject to additional disclosure.   Income Taxes   The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 Income Taxes.  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.   Intangible Assets Patent and Patent Application Costs   The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.   As at June 30, 2017, the Company does not hold any intangible assets with indefinite lives.   Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.   Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.   Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Companys patents, whereas no amortization has been recognized on the patent application costs as at June 30, 2017.   Research and Development Costs   Research and development costs are expensed as incurred.   Loss per Share and Potentially Dilutive Securities   Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of 44,100,000 stock options (June 30, 2016 28,600,000), and 6,500,000 warrants (June 30, 2016 6,500,000) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.   Share-Based Compensation   The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.   The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 Compensation Stock Compensation, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Companys stock price on the date of issuance.   The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 Stock-Based Transactions with Nonemployees, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.   Common stock   Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterpartys performance is complete.   Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.   Related Party Transactions   A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.   Recent Accounting Pronouncements   In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entitys Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entitys ability to continue as a going concern within one year of the date of issuance of the entitys financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entitys ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance did not have a material impact on the Companys financial statements.   Accounting Standards Update 2015-17 Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy was effective for periods ending after December 16, 2016. The adoption of this guidance did not have a material impact on the Companys financial statements.   Accounting Standards Update 2016-09 CompensationStock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect for periods ending after December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The adoption of this guidance did not have a material impact on the Companys financial statements.   Accounting Standards Update 2016-01 Financial Instruments Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements.   Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements.

The following summarizes the Companys prepaid expenses and deposits outstanding as at June 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid"> June 30, 2017</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid"> December 31, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 68%; text-align: justify">Deposit on research agreement (Note 11(c))</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">134,370</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">54,770</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: top; padding-bottom: 1.3pt; text-align: justify">Other prepaid expenses</td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt; text-align: right">8,130</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">15,614</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: top; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">142,500</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">70,384</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> </table>

Intangible asset transactions are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Patent Rights</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Patent Application Rights</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td></tr> <tr> <td style="vertical-align: top; text-align: justify">Cost</td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 53%; text-align: justify">Balance, December 31, 2015</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">30,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">41,760</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 12%; text-align: right">71,760</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: top; padding-bottom: 1.3pt; text-align: justify">Additions</td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt; text-align: right">33,421</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">33,421</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance, December 31, 2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">30,000</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">75,181</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">105,181</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: top; padding-bottom: 1.3pt; text-align: justify">Additions</td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt; text-align: right">51,992</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">51,992</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: justify">Balance, June 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">30,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">127,173</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">157,173</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Accumulated amortization</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: top; text-align: justify">Balance, December 31, 2015</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 1.3pt; text-align: justify">Amortization</td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt; text-align: right">3,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">3,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td></tr> <tr> <td style="vertical-align: top; text-align: justify">Balance, December 31, 2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">4,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">4,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 1.3pt; text-align: justify">Amortization</td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt; text-align: right">1,500</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.3pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">1,500</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.3pt"> </td></tr> <tr> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: justify">Balance, June 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: top; text-align: justify">Net carrying amounts</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">December 31, 2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">25,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">75,181</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">100,681</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: justify">June 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">24,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">127,173</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">151,173</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> </table>     During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the Patent Assignment) with the Institut National des Sciences Appliquees de Rouen (INSA) for the assignment of certain patents and all rights associated therewith (the Patents). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $30,000 (25,000 Euros) (paid). During the six month period ended June 30, 2017, the Company recorded $1,500 (June 30, 2016 - $1,500) in amortization expense associated with the Patents.   During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the "Patent Application Rights").  In exchange for the Patent Application Rights, the Company agreed to pay $10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company has incurred $78,692 in direct costs relating to the Patent Application Rights, $40,922 of which were incurred during the six month period ended June 30, 2017.   The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty.   During the year ended December 31, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells (the New Patent Application Rights).  In exchange for the New Patent Application Rights, the Company agreed to pay $1 (paid).  The Company has incurred $13,481 in direct costs relating to the New Patent Application Rights, $11,065 of which were incurred during the six month period ended June 30, 2017.   No amortization was recorded on the Patent Application Rights to June 30, 2017.

On June 16, 2016, the Company executed a line of credit arrangement for an amount of up to $250,000 with Pleasants County Bank, West Virginia.  Pursuant to the terms of the line of credit, interest will accrue on the amount of credit outstanding at a rate of 1.5% above the prime rate adjusted monthly.  The Companys President and CEO pledged personal assets to secure the line of credit and the Company pledged its patent rights in the provisional patent application numbered 62287857, dated January 21, 2016, Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells. As at March 31, 2017 and December 31, 2016, the balance outstanding was $nil.  As of June 30, 2017 the line of credit was canceled and the pledged assets were released.

During the six month periods ended June 30, 2017 and 2016, the Company issued shares of common stock for services and other value rendered as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">   2017</td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value per Share</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 53%; text-align: justify">January - June 2017</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 13%; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 12%; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: top; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 2.55pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.55pt; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2.55pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">   2016</td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value per Share</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 53%; text-align: justify">March 2016</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 13%; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">0.07</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 12%; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: top; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 2.55pt; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.55pt; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.55pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2.55pt"> </td></tr> </table>

On December 30, 2016, the Board of Directors of the Company adopted the 2017 Stock Option and Stock Bonus Plan (the 2017 Plan).  The Board of Directors adopted the 2017 Plan as it anticipates utilizing equity compensation as part of its ongoing standard corporate operations and in connection with its contemplated activities going forward.   The aggregate number of shares that may be issued under the 2017 Plan is 30,000,000 shares subject to adjustment as provided therein.  The 2017 Plan includes two types of options.  Options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended are referred to as incentive options.  Options which are not intended to qualify as incentive options are referred to as non-qualified options.   As of June 30, 2017, 16,200,000 options and no shares of common stock have been granted under the 2017 Plan.   The 2017 Plan is administered by the Board of Directors, or a committee appointed by the Board of Directors.  In addition to determining who will be granted options or stock bonuses, the committee has the authority and discretion to determine when options and bonuses will be granted and the number of options and bonuses to be granted.  The committee also may determine a vesting and/or forfeiture schedule for bonuses and/or options granted, the time or times when each option becomes exercisable, the duration of the exercise period for options and the form or forms of the agreements, certificates or other instruments evidencing grants made under the 2017 Plan.  The committee may determine the purchase price of the shares of common stock covered by each option.  The committee also may impose additional conditions or restrictions not inconsistent with the provisions of the 2017 Plan.  The committee may adopt, amend and rescind such rules and regulations as in its opinion may be advisable for the administration of the 2017 Plan.    In the event that a change, such as a stock split, is made in the Companys capitalization which results in an exchange or other adjustment of each share of common stock for or into a greater or lesser number of shares, appropriate adjustments will be made to unvested bonuses and in the exercise price and in the number of shares subject to each outstanding option.  The committee also may make provisions for adjusting the number of bonuses or underlying outstanding options in the event the Company effects one or more reorganizations, recapitalizations, rights offerings, or other increases or reductions of shares of its outstanding common stock.  Options and bonuses may provide that in the event of the dissolution or liquidation of the Company, a corporate separation or division or the merger or consolidation of the Company, the holder may exercise the option on such terms as it may have been exercised immediately prior to such dissolution, corporate separation or division or merger or consolidation; or in the alternative, the committee may provide that each option granted under the 2017 Plan shall terminate as of a date fixed by the committee.   The exercise price of any option granted under the 2017 Plan must be no less than 100% of the fair market value of the Companys common stock on the date of grant.  The exercise period of any option shall not exceed ten years from the date of grant of the option. Any incentive stock option granted under the 2017 Plan to a person owning more than 10% of the total combined voting power of the common stock must be at a price of no less than 110% of the fair market value per share on the date of grant and the term shall be for no more than five years.    Stock option transactions are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Stock Options</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Fair Value</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid"> Weighted Average Remaining Life</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">$</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">$ </td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">(Years)</td></tr> <tr style="vertical-align: bottom"> <td style="width: 51%">Outstanding, December 31, 2016</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">28,900,000</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">0.06</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">0.04</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 10%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>      Options granted</td> <td> </td> <td> </td> <td style="text-align: right">16,200,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">0.05</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">0.06</td> <td nowrap="nowrap"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">      Options expired</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,000,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid">)</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.10</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.03</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double">Outstanding, June 30, 2017</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">44,100,000</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">0.06</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">0.05</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2.72</td></tr> </table>   The fair values of the stock options granted during the six month periods ended June 30, 2017 and 2016 were estimated using the Black-Scholes Option Pricing Model.  The weighted average assumptions used in the pricing model for these options are as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">June 30, 2017</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">June 30, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 69%; text-indent: 0.05in">Risk-free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">1.05</td> <td nowrap="nowrap" style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">0.56</td> <td nowrap="nowrap" style="width: 1%">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: 0.05in">Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td nowrap="nowrap">%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td nowrap="nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: 0.05in">Expected stock price volatility</td> <td> </td> <td> </td> <td style="text-align: right">125.00</td> <td nowrap="nowrap">%</td> <td> </td> <td> </td> <td style="text-align: right">125.00</td> <td nowrap="nowrap">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: 0.05in">Expected forfeiture rate</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td nowrap="nowrap">%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td nowrap="nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; text-indent: 0.05in">Expected life</td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right">3.46 years</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right">3.94 years</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> </table>   The following non-qualified stock options were outstanding and exercisable at June 30, 2017:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Expiry date</td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options Outstanding</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options Exercisable</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$  </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">February 25, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">0.04</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">2,000,000</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">-</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>February 24, 2018</td> <td> </td> <td> </td> <td style="text-align: right">0.05</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td>February 25, 2020</td> <td> </td> <td> </td> <td style="text-align: right">0.04</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">4,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">4,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>February 28, 2020</td> <td> </td> <td> </td> <td style="text-align: right">0.04</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">5,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">5,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td>June 30, 2018</td> <td> </td> <td> </td> <td style="text-align: right">0.10</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>December 31, 2019</td> <td> </td> <td> </td> <td style="text-align: right">0.08</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">15,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">15,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td>October 05, 2018</td> <td> </td> <td> </td> <td style="text-align: right">0.08</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">300,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">300,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid">December 31, 2020</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.05</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">16,200,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">8,100,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"> </td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">44,100,000</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">34,000,000</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td></tr> </table>   As at June 30, 2017, the aggregate intrinsic value of the Companys stock options is $674,000 (December 31, 2016 $110,000). The weighted average fair value of stock options granted during the six month period ended June 30, 2017 is $0.06 (2016 - $0.05).

The Company is authorized to issue 400,000,000 (December 31, 2016 400,000,000) shares of $0.0000053 par value common stock.  Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of June 30, 2017 (December 31, 2016 - $nil).   During the six month period ended June 30, 2017, the Company:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: 8pt Times New Roman, Times, Serif">a)</td> <td style="width: 96%; font: 8pt Times New Roman, Times, Serif; text-align: justify">Issued 8,000,000 shares of common stock to investors (which included both the President and CEO as well as the CFO of the Company) at $0.04 for gross proceeds of $320,000.</td></tr> </table>

Note 10. Related Party Transactions and Balances   During the six month period ended June 30, 2016, the Company:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">a)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2016 with the Companys President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Companys President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control.  In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of an Application Sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement.  Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7).  The options are fully vested as at June 30, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">b)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2016 with the Companys CFO whereby she will be compensated at a monthly fee of $6,000 for services through to December 31, 2016.  The agreement also stipulates a termination fee that would pay the Companys CFO $36,000 if terminated without cause or $72,000 upon termination due to a change of control event.  Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7).  The options are fully vested as at June 30, 2017.  A total of $36,000 was paid to the Companys CFO during the period ended June 30, 2016.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">c)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a directorship agreement with an effective date of January 1, 2016 with a director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options are fully vested as at June 30, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">d)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Recognized $271,850 in share-based compensation associated with stock options granted to key management personnel.</td></tr> </table>   During the six months ended June 30, 2017, the Company:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">a)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2017 with the Companys President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2017. The agreement also stipulates a termination fee that would pay the Companys President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control.  In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of a sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement.  Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note7).  The options vest in equal instalments on a quarterly basis beginning March 31, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">b)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2017 with the Companys CFO whereby she will be compensated at a monthly fee of $6,000 for services through to December 31, 2017.  The agreement also stipulates a termination fee that would pay the Companys CFO $72,000 per year of service (including the pro-rata amount for partial years of service) if terminated without cause or upon termination due to a change of control event.  Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7).  The options vest in equal instalments on a quarterly basis beginning March 31, 2017.  A total of $36,000 was paid to the Companys CFO during the period ended June 30, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">c)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a directorship agreement with an effective date of January 1, 2017 with a director of the Company.  Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7).  The options vest in equal instalments on a quarterly basis beginning March 31, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">d)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Recognized $198,274 in share-based compensation associated with stock options granted to key management personnel.</td></tr> </table>   As at June 30, 2017 and December 31, 2016, the following amounts are due to related parties:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr> <td style="vertical-align: top; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td style="vertical-align: top; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">June 30,2017</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">December 31, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">Clarence Smith (CEO)</td> <td style="vertical-align: top; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">Accounts payable and accrued liabilities</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">-</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify">81</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1pt solid; font-weight: bold; text-align: justify"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   Amounts included in accounts payable and accrued liabilities are non-interest bearing, unsecured and repayable on demand.

As at June 30, 2017, the Company has the following commitments:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">a)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2017 whereby the Company would pay the consultant $7,000 per month for providing research and development services.  Pursuant to the agreement, the consultant was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7).  The options vest in equal instalments on a quarterly basis beginning March 31, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">b)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement for business development services effective January 1, 2017.  The consultant was granted 1,200,000 stock options exercisable into common shares of the Company at a price of $0.05 per share until December 31, 2020 (Note 7).  The options vest in equal instalments on a quarterly basis beginning March 31, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">c)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a Collaborative Research Agreement (the CREA) effective May 31, 2016 with The University of British Columbia (UBC) for a term of 2 years. Pursuant to the CREA, the Company paid a total of CAD $169,000 ($131,448) in advance for services to be provided by UBC in the first year, and paid an additional CAD $201,500 ($146,585) during the six month period ended June 30, 2017, in advance of services to be provided by UBC in the second year. The CREA can be terminated by either party with 30 days written notice.  As at June 30, 2017, a total of $134,370 is included in prepaid expenses and deposits (December 31, 2016 - $54,770).</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">d)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement effective March 1, 2015, whereby the Company would pay the consultant $2,700 per month for an initial term of 1 year, continued on a year-to-year basis thereafter unless otherwise terminated by either party with at least 30 days notice, for providing public relations services. The consultant is also entitled to 400,000 shares of common stock, which will be issued at a rate of 25% (100,000 shares) every 3 months over the term of the agreement (200,000 shares issued during the six month period ended June 30, 2016 (Note 6)). The consultant was also issued 1,000,000 stock options on signing during the year ended December 31, 2015, with each stock option exercisable into a common share at a price of $0.10. The stock options expired March 12, 2016.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">e)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a royalty agreement with the Governors of the University of Alberta (the University) whereby the University had developed certain intellectual property (the Additional Patent Rights) in conjunction with and by permission of the Company employing patented intellectual property of the Company. The agreement assigns the Additional Patent Rights to the Company in return for 5% of any future gross revenues (the Royalty) derived from products arising from the Patent Rights. The Company will have the right and option for two years from the earlier of September 1, 2015 or the first date that the University publishes its research related to the Additional Patent Rights to buy out all of the Universitys Royalty for consideration of the aggregate sum of CAD $5,000,000.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">f)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement effective May 1, 2015, whereby the Company would pay the consultant $4,000 per month for an initial term of 1 year, continued on a year-to-year basis thereafter unless otherwise terminated by either party with at least 30 days notice  for providing research and development services.  During the six month period ended June 30, 2017 the contract was revised whereby the Company would pay the consultant CAD $4,000 per month retroactively beginning January 1, 2017.  As a result of the revision, an amount of $8,130 is included within prepaid expenses as at June 30, 2017 and will be applied towards future services.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">g)</td> <td style="width: 96%; font: bold 8pt Times New Roman, Times, Serif; text-align: justify">Entered into a Material Transfer Agreement effective March 31, 2017 with Proactive Immune Sciences Corporation (Proactive) for a term of 1 year.  The Company will furnish AAGP at no cost to Proactive so that they may test and evaluate AAGP for possible use in Immune Cell Banking.</td></tr> </table>   The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, Report of Foreign Bank and Financial Accounts (FBARs). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs.  Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no underreported tax liabilities.  The Company may be liable for civil penalties for certain tax years in an indeterminate amount for not complying with the FBAR reporting and recordkeeping requirements.  No claim has been asserted by the U.S. Internal Revenue Service; before any claim is expressly asserted the Company intends to cooperate with the Internal Revenue Service to minimize any liability. The Company is unable to determine the amount of any penalties that may be assessed at this time.

The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (US GAAP) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Companys audited financial statements and notes thereto for the year ended December 31, 2016, included in the Companys Annual Report on Form 10-K, filed February 21, 2017, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.

Cash consists of funds held in checking accounts.  Cash balances may exceed federally insured limits from time to time.

Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.   The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 Fair Value Measurements and Disclosures which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:   Level 1 quoted prices in active markets for identical assets or liabilities Level 2 quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 inputs that are unobservable (for example cash flow modeling inputs based on assumptions)   Level 1 inputs are used to measure cash. At June 30, 2017 there were no other assets or liabilities subject to additional disclosure.

The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 Income Taxes.  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.

The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.   As at June 30, 2017, the Company does not hold any intangible assets with indefinite lives.   Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.   Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.   Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Companys patents, whereas no amortization has been recognized on the patent application costs as at June 30, 2017.

Research and development costs are expensed as incurred.

Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of 44,100,000 stock options (June 30, 2016 28,600,000), and 6,500,000 warrants (June 30, 2016 6,500,000) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.

The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.   The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 Compensation Stock Compensation, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Companys stock price on the date of issuance.   The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 Stock-Based Transactions with Nonemployees, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterpartys performance is complete.   Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entitys Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entitys ability to continue as a going concern within one year of the date of issuance of the entitys financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entitys ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance did not have a material impact on the Companys financial statements.   Accounting Standards Update 2015-17 Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy was effective for periods ending after December 16, 2016. The adoption of this guidance did not have a material impact on the Companys financial statements.   Accounting Standards Update 2016-09 CompensationStock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect for periods ending after December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The adoption of this guidance did not have a material impact on the Companys financial statements.   Accounting Standards Update 2016-01 Financial Instruments Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements.   Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements.

Intangible asset transactions are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">Patent Rights</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Patent Application Rights</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">Total</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"> </td></tr> <tr> <td style="vertical-align: top; font-weight: bold; text-align: justify">Cost</td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td colspan="2" style="vertical-align: top; font-weight: bold"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td colspan="2" style="vertical-align: top; font-weight: bold"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td colspan="2" style="vertical-align: top; font-weight: bold"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 53%; font-weight: bold; text-align: justify">Balance, December 31, 2015</td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold">$</td> <td style="vertical-align: bottom; width: 12%; font-weight: bold; text-align: right">30,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold">$</td> <td style="vertical-align: bottom; width: 13%; font-weight: bold; text-align: right">41,760</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold">$</td> <td style="vertical-align: bottom; width: 13%; font-weight: bold; text-align: right">71,760</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Additions</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: right">33,421</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">33,421</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; font-weight: bold; text-align: justify">Balance, December 31, 2016</td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold">$</td> <td style="vertical-align: bottom; font-weight: bold; text-align: right">30,000</td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold">$</td> <td style="vertical-align: bottom; font-weight: bold; text-align: right">75,181</td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold">$</td> <td style="vertical-align: bottom; font-weight: bold; text-align: right">105,181</td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Additions</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: right">51,992</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">51,992</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 2.25pt double; font-weight: bold; text-align: justify">Balance, June 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">30,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">127,173</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">157,173</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; font-weight: bold; text-align: justify">Accumulated amortization</td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; font-weight: bold; text-align: justify">Balance, December 31, 2015</td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold">$</td> <td style="vertical-align: bottom; font-weight: bold; text-align: right">1,500</td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold">$</td> <td style="vertical-align: bottom; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold">$</td> <td style="vertical-align: bottom; font-weight: bold; text-align: right">1,500</td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Amortization</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: right">3,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">3,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; font-weight: bold; text-align: justify">Balance, December 31, 2016</td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold">$</td> <td style="vertical-align: bottom; font-weight: bold; text-align: right">4,500</td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold">$</td> <td style="vertical-align: bottom; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold">$</td> <td style="vertical-align: bottom; font-weight: bold; text-align: right">4,500</td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Amortization</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: right">1,500</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">1,500</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; border-bottom: black 2.25pt double; font-weight: bold; text-align: justify">Balance, June 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">6,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">6,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; font-weight: bold; text-align: justify">Net carrying amounts</td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; font-weight: bold; text-align: justify">December 31, 2016</td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold">$</td> <td style="vertical-align: bottom; font-weight: bold; text-align: right">25,500</td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold">$</td> <td style="vertical-align: bottom; font-weight: bold; text-align: right">75,181</td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold"> </td> <td style="vertical-align: bottom; font-weight: bold">$</td> <td style="vertical-align: bottom; font-weight: bold; text-align: right">100,681</td> <td nowrap="nowrap" style="vertical-align: bottom; font-weight: bold"> </td></tr> <tr> <td style="vertical-align: top; border-bottom: black 2.25pt double; font-weight: bold; text-align: justify">June 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">24,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">127,173</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">151,173</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2017</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%; font-weight: bold; text-indent: 0.05in">Risk-free interest rate</td> <td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold"> </td> <td style="width: 13%; font-weight: bold; text-align: right">1.05</td> <td nowrap="nowrap" style="width: 1%; font-weight: bold">%</td> <td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold"> </td> <td style="width: 11%; font-weight: bold; text-align: right">0.56</td> <td nowrap="nowrap" style="width: 1%; font-weight: bold">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-indent: 0.05in">Dividend yield</td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">0.00</td> <td nowrap="nowrap" style="font-weight: bold">%</td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">0.00</td> <td nowrap="nowrap" style="font-weight: bold">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-weight: bold; text-indent: 0.05in">Expected stock price volatility</td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">125.00</td> <td nowrap="nowrap" style="font-weight: bold">%</td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">125.00</td> <td nowrap="nowrap" style="font-weight: bold">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-indent: 0.05in">Expected forfeiture rate</td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">0.00</td> <td nowrap="nowrap" style="font-weight: bold">%</td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">0.00</td> <td nowrap="nowrap" style="font-weight: bold">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; font-weight: bold; text-indent: 0.05in">Expected life</td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">3.46 years</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">3.94 years</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; font-weight: bold">Expiry date</td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options Outstanding</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options Exercisable</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">$  </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%; font-weight: bold">February 25, 2020</td> <td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold"> </td> <td style="width: 13%; font-weight: bold; text-align: right">0.04</td> <td nowrap="nowrap" style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold"> </td> <td style="width: 13%; font-weight: bold; text-align: right">2,000,000</td> <td nowrap="nowrap" style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold"> </td> <td style="width: 13%; font-weight: bold; text-align: right">-</td> <td nowrap="nowrap" style="width: 1%; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-weight: bold">February 24, 2018</td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">0.05</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">1,000,000</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">1,000,000</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">February 25, 2020</td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">0.04</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">4,000,000</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">4,000,000</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-weight: bold">February 28, 2020</td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">0.04</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">5,000,000</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">5,000,000</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">June 30, 2018</td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">0.10</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">600,000</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">600,000</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-weight: bold">December 31, 2019</td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">0.08</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">15,000,000</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">15,000,000</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">October 05, 2018</td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">0.08</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">300,000</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: right">300,000</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; font-weight: bold">December 31, 2020</td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">0.05</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">16,200,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">8,100,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="border-bottom: black 2.25pt double; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="border-bottom: black 2.25pt double; font-weight: bold; text-align: right">44,100,000</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="border-bottom: black 2.25pt double; font-weight: bold; text-align: right">34,000,000</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double; font-weight: bold"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 2.25pt double; font-weight: bold; text-align: justify">Balance, December 31, 2016 and June 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">6,500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">0.11</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td></tr> <tr> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center; text-indent: 21pt">Number of Warrants</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price ($)</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="border-bottom: black 1.5pt solid">   Expiry Date</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 30%; font-weight: bold; text-align: right">500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: bottom; width: 31%; font-weight: bold; text-align: right">0.25</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-weight: bold"> </td> <td style="vertical-align: top; width: 34%; font-weight: bold; text-align: right">November 8, 2018</td></tr> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">6,000,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">0.10</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font-weight: bold"> </td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font-weight: bold; text-align: right">April 22, 2020</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right">6,500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double; font-weight: bold"> </td> <td style="vertical-align: top; border-bottom: black 2.25pt double; font-weight: bold"> </td></tr> </table>

237952433

245952433

8000000

EX-101.SCH 7 pktx-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 1. Basis of Presentation - Going Concern Uncertainties link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 2. Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 3. Prepaid Expenses and Deposits link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 4. Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 5. Credit Facility link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 6. Common Shares Issued for Services link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 7. Stock Options link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 8. Warrants link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 9. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 10. Related Party Transactions and Balances link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 11. Commitments and Contingency link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 3. Prepaid Expenses and Deposits (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 4. Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 6. Common Shares Issued for Services (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 7. Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 8. Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 10. Related Party Transactions and Balances (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 3. Prepaid Expenses and Deposits (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 4. Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 4. Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 5. Credit Facility (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 6. Common Shares Issued for Services (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 7. Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 7. Stock Options (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 7. Stock Options (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 7. Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 8. Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 8. Warrants (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 9. Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - 10. Related Party Transactions and Balances (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - 10. Related Party Transactions and Balances (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - 11. Commitments and Contingency (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 pktx-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 pktx-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 pktx-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Finite-Lived Intangible Assets by Major Class [Axis] Patent Rights [Member] Range [Axis] Cost [Member] Patent Application Rights [Member] Total [Member] Accumulated Amortization [Member] Net Carrying Amount [Member] Related Party [Axis] Clarence Smith (CEO) Statement, Equity Components [Axis] Common Stock Additional paid-in capital Accumulated Deficit Antidilutive Securities [Axis] Warrant Award Type [Axis] Stock options March 2016 January - March 2017 Exercise Price Range [Axis] February 25, 2020 February 24, 2018 February 28, 2020 December 31, 2020 December 31, 2019 October 05, 2018 February 25, 2020 One Options Warrant One Warrant Two Equity Components [Axis] Additional Paid-In Capital June 30, 2018 Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Document Period End Date Trading Symbol Current Fiscal Year End Date Entity Filer Category Entity Voluntary Filers Entity Well Known Seasoned Issuer Entity Current Reporting Status Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Prepaid expenses and deposits (Notes 3 and 11) Total current assets Intangible assets (Note 4) Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable and accrued liabilities (Note 10) Total current liabilities Stockholders' Equity Common stock, $0.0000053 par value; 400,000,000 common shares authorized; 245,952,433 and 237,952,433 shares issued and outstanding as at June 30, 2017 and December 31, 2016 respectively (Note 9) Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Common Stock, Par Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] EXPENSES Amortization - intangible assets (Note 4) General and administrative Professional fees (Note 10) Research and development Share-based compensation (Note 10) Total OTHER ITEM Foreign exchange loss Net loss for the period Net loss per common share (basic and diluted) Weighted average number of common shares outstanding (basic and diluted) Statement [Table] Statement [Line Items] Beginning Balance, Shares Beginning Balance, Amount Issuance of common stock pursuant to private placement offering, shares Issuance of common stock pursuant to private placement offering, amount Fair value of compensatory options issued Net loss for the period Ending Balance, Shares Ending Balance, Amount Statement of Cash Flows [Abstract] CASH FLOWS USED IN OPERATING ACTIVITIES Adjustments to reconcile net loss to cash used in operating activities: Amortization - intangible assets Issuance and amortization of common stock for services Fair value of compensatory options granted Changes in operating assets and liabilities: Prepaid expenses and deposits Accounts payable and accrued liabilities Net cash used in operating activities CASH FLOWS USED IN INVESTING ACTIVITIES Purchase of Intangible assets Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Issuance of common stock for cash Net cash from financing activities Net change in cash Cash, beginning of period Cash, end of period Cash paid for interest Cash paid for income taxes Supplementary information - non-cash transactions: Common stock issued for consulting services Intangible asset costs previously included in accounts payable and accrued liabilities Intangible asset costs previously included in prepaid expenses and deposits Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation - Going Concern Uncertainties Accounting Policies [Abstract] Summary of Significant Accounting Policies Prepaid Expenses And Deposits Prepaid Expenses and Deposits Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Debt Disclosure [Abstract] Credit Facility Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Common Shares Issued for Services Stock Options Stock Options Warrants Warrants Stockholders' Equity Note [Abstract] Stockholders' Equity Related Party Transactions [Abstract] Related Party Transactions and Balances Commitments and Contingencies Disclosure [Abstract] Commitments and Contingency Basis of Presentation Use of Estimates Cash Fair Value of Financial Instruments Income Taxes Intangible Assets - Patent and Patent Application Costs Research and Development Costs Loss per Share and Potentially Dilutive Securities Share-Based Compensation Common stock Related Party Transactions Recent Accounting Pronouncements Prepaid Expenses And Deposits Tables Prepaid expenses and deposits Intangible asset transactions Schedule of Stock Incentive Plan, Issuances Schedule of Share-based Compensation, Stock Options, Activity Schedule of valuation assumptions for options Schedule of options by exercise price Schedule of Warrant Activity Schedule of Stockholders' Equity Note, Warrants or Rights Schedule of related party transactions Antidilutive Securities Excluded from Computation of Earnings Per Share Prepaid Expenses And Deposits Details Deposit on research agreement (Note 11(c)) Other prepaid expenses Prepaid expenses and deposits Beginning balance Additions Amortization Ending balance Line of credit Number of Shares Value per Share Total Outstanding, beginning Options granted Options expired Outstanding, ending Weighted Average Exercise Price beginning Weighted Average Exercise Price, granted Weighted Average Exercise Price, expired Weighted Average Exercise Price ending Weighted Average Fair Value, beginning Weighted Average Fair Value, granted Weighted Average Fair Value, expired Weighted Average Fair Value, ending Weighted Average Remaining Life (Years) Risk-free interest rate Dividend yield Expected stock price volatility Expected forfeiture rate Expected life Exercise Price Number of Options Outstanding Number of options exercisable Common stock granted Aggregate intrinsic value Weighted average fair value of stock options granted per share EX-101.PRE 11 pktx-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 08, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	ProtoKinetix, Inc.
Entity Central Index Key	0001128189
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Trading Symbol	pktx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		245,952,433
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current Assets
Cash	$ 238,277	$ 371,029
Prepaid expenses and deposits (Notes 3 and 11)	142,500	70,384
Total current assets	380,777	441,413
Intangible assets (Note 4)	151,173	100,681
Total assets	531,950	542,094
Current Liabilities
Accounts payable and accrued liabilities (Note 10)	5,369	45,295
Total current liabilities	5,369	45,295
Stockholders' Equity
Common stock, $0.0000053 par value; 400,000,000 common shares authorized; 245,952,433 and 237,952,433 shares issued and outstanding as at June 30, 2017 and December 31, 2016 respectively (Note 9)	1,316	1,273
Additional paid-in capital	29,852,293	29,115,795
Accumulated deficit	(29,327,028)	(28,620,269)
Total stockholders' equity	526,581	496,799
Total liabilities and stockholders' equity	$ 531,950	$ 542,094

XML 14 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common Stock, Par Value Per Share	$ 0.0000053	$ 0.0000053
Common Stock, Shares Authorized	400,000,000	400,000,000
Common Stock, Shares, Issued	245,952,433	237,952,433
Common Stock, Shares, Outstanding	245,952,433	237,952,433

XML 15 R4.htm IDEA: XBRL DOCUMENT

STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
EXPENSES
Amortization - intangible assets (Note 4)	$ 750	$ 750	$ 1,500	$ 1,500
General and administrative	29,804	29,503	61,937	50,934
Professional fees (Note 10)	24,322	41,806	67,274	108,313
Research and development	86,235	108,481	155,273	180,132
Share-based compensation (Note 10)	186,025	190,244	416,541	374,763
Total	(327,136)	(370,784)	(702,525)	(715,642)
OTHER ITEM
Foreign exchange loss	(4,259)	(2,169)	(4,234)	(2,166)
Net loss for the period	$ (331,395)	$ (372,953)	$ (706,759)	$ (717,808)
Net loss per common share (basic and diluted)	$ (0.00)	$ 0.00	$ (0.00)	$ (0.00)
Weighted average number of common shares outstanding (basic and diluted)	245,952,433	217,340,895	228,044,331	216,988,147

XML 16 R5.htm IDEA: XBRL DOCUMENT

STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) - 6 months ended Jun. 30, 2017 - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Shares at Dec. 31, 2016	237,952,433
Beginning Balance, Amount at Dec. 31, 2016	$ 1,273	$ 29,115,795	$ (28,620,269)	$ 496,799
Issuance of common stock pursuant to private placement offering, shares	8,000,000
Issuance of common stock pursuant to private placement offering, amount	$ 43	319,957		320,000
Fair value of compensatory options issued		416,541		416,541
Net loss for the period			(706,759)	(706,759)
Ending Balance, Shares at Jun. 30, 2017	245,952,433
Ending Balance, Amount at Jun. 30, 2017	$ 1,316	$ 29,852,293	$ (29,327,028)	$ 526,581

XML 17 R6.htm IDEA: XBRL DOCUMENT

STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS USED IN OPERATING ACTIVITIES
Net loss for the period	$ (706,759)	$ (717,808)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization - intangible assets	1,500	1,500
Issuance and amortization of common stock for services		7,000
Fair value of compensatory options granted	416,541	374,763
Changes in operating assets and liabilities:
Prepaid expenses and deposits	(87,730)	(154,198)
Accounts payable and accrued liabilities	(36,295)	66,722
Net cash used in operating activities	(412,743)	(422,021)
CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of Intangible assets	(40,009)	(6,538)
Net cash used in investing activities	(40,009)	(6,538)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock for cash	320,000	166,000
Net cash from financing activities	320,000	166,000
Net change in cash	(132,752)	(262,559)
Cash, beginning of period	371,029	371,072
Cash, end of period	238,277	108,513
Cash paid for interest
Cash paid for income taxes
Supplementary information - non-cash transactions:
Common stock issued for consulting services		7,000
Intangible asset costs previously included in accounts payable and accrued liabilities	3,631
Intangible asset costs previously included in prepaid expenses and deposits	$ 15,614

XML 18 R7.htm IDEA: XBRL DOCUMENT

1. Basis of Presentation - Going Concern Uncertainties

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation - Going Concern Uncertainties

During the year ended December 31, 2016, the Company filed Form 51-105F1 – Notice – OTC Issuer Ceases to be an OTC Reporting Issuer with the British Columbia Securities Commission (“BCSC”).

The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.

XML 19 R8.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Cash

Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.

Fair Value of Financial Instruments

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Level 1 inputs are used to measure cash. At June 30, 2017 there were no other assets or liabilities subject to additional disclosure.

Income Taxes

Intangible Assets – Patent and Patent Application Costs

As at June 30, 2017, the Company does not hold any intangible assets with indefinite lives.

Research and Development Costs

Research and development costs are expensed as incurred.

Loss per Share and Potentially Dilutive Securities

Share-Based Compensation

Common stock

Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

Related Party Transactions

Recent Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

3. Prepaid Expenses and Deposits

6 Months Ended

Jun. 30, 2017

Prepaid Expenses And Deposits

Prepaid Expenses and Deposits

The following summarizes the Company’s prepaid expenses and deposits outstanding as at June 30, 2017 and December 31, 2016:

	June 30, 2017		December 31, 2016

Deposit on research agreement (Note 11(c))	$	134,370	$	54,770
Other prepaid expenses		8,130		15,614

	$	142,500	$	70,384

XML 21 R10.htm IDEA: XBRL DOCUMENT

4. Intangible Assets

6 Months Ended

Jun. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangible asset transactions are summarized as follows:

	Patent Rights		Patent Application Rights		Total
Cost
Balance, December 31, 2015	$	30,000	$	41,760	$	71,760
Additions		-		33,421		33,421
Balance, December 31, 2016	$	30,000	$	75,181	$	105,181
Additions		-		51,992		51,992
Balance, June 30, 2017	$	30,000	$	127,173	$	157,173

Accumulated amortization
Balance, December 31, 2015	$	1,500	$	-	$	1,500
Amortization		3,000		-		3,000
Balance, December 31, 2016	$	4,500	$	-	$	4,500
Amortization		1,500		-		1,500
Balance, June 30, 2017	$	6,000	$	-	$	6,000

Net carrying amounts
December 31, 2016	$	25,500	$	75,181	$	100,681
June 30, 2017	$	24,000	$	127,173	$	151,173

The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty.

No amortization was recorded on the Patent Application Rights to June 30, 2017.

XML 22 R11.htm IDEA: XBRL DOCUMENT

5. Credit Facility	6 Months Ended
5. Credit Facility	Jun. 30, 2017
Debt Disclosure [Abstract]
Credit Facility	On June 16, 2016, the Company executed a line of credit arrangement for an amount of up to $250,000 with Pleasants County Bank, West Virginia. Pursuant to the terms of the line of credit, interest will accrue on the amount of credit outstanding at a rate of 1.5% above the prime rate adjusted monthly. The Company’s President and CEO pledged personal assets to secure the line of credit and the Company pledged its patent rights in the provisional patent application numbered 62287857, dated January 21, 2016, “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells”. As at March 31, 2017 and December 31, 2016, the balance outstanding was $nil. As of June 30, 2017 the line of credit was canceled and the pledged assets were released.

XML 23 R12.htm IDEA: XBRL DOCUMENT

6. Common Shares Issued for Services

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Common Shares Issued for Services

During the six month periods ended June 30, 2017 and 2016, the Company issued shares of common stock for services and other value rendered as follows:

2017	Number of Shares		Value per Share		Total

January - June 2017		-	$	-	$	-
		-			$	-

2016	Number of Shares		Value per Share		Total

March 2016		100,000	$	0.07	$	7,000
		100,000			$	7,000

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

7. Stock Options

6 Months Ended

Jun. 30, 2017

Stock Options

Stock Options

As of June 30, 2017, 16,200,000 options and no shares of common stock have been granted under the 2017 Plan.

Stock option transactions are summarized as follows:

	Number of Stock Options			Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Life
				$		$		(Years)
Outstanding, December 31, 2016		28,900,000			0.06		0.04
Options granted		16,200,000			0.05		0.06
Options expired		(1,000,000	)		0.10		0.03
Outstanding, June 30, 2017		44,100,000			0.06		0.05	2.72

	June 30, 2017			June 30, 2016
Risk-free interest rate		1.05	%		0.56	%
Dividend yield		0.00	%		0.00	%
Expected stock price volatility		125.00	%		125.00	%
Expected forfeiture rate		0.00	%		0.00	%
Expected life	3.46 years			3.94 years

The following non-qualified stock options were outstanding and exercisable at June 30, 2017:

Expiry date	Exercise Price		Number of Options Outstanding		Number of Options Exercisable
					$
February 25, 2020		0.04		2,000,000		-
February 24, 2018		0.05		1,000,000		1,000,000
February 25, 2020		0.04		4,000,000		4,000,000
February 28, 2020		0.04		5,000,000		5,000,000
June 30, 2018		0.10		600,000		600,000
December 31, 2019		0.08		15,000,000		15,000,000
October 05, 2018		0.08		300,000		300,000
December 31, 2020		0.05		16,200,000		8,100,000
				44,100,000		34,000,000

XML 25 R14.htm IDEA: XBRL DOCUMENT

8. Warrants

6 Months Ended

Jun. 30, 2017

Warrants

Warrants

Warrant transactions for the six month period ended June 30, 2017 are summarized as follows:

Number of

Warrants

Weighted

Average Exercise

Price

Balance, December 31, 2016 and June 30, 2017

6,500,000

0.11

The following warrants were outstanding and exercisable as at June 30, 2017:

Number of Warrants		Exercise Price ($)		Expiry Date
	500,000		0.25	November 8, 2018
	6,000,000		0.10	April 22, 2020
	6,500,000

XML 26 R15.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity

6 Months Ended

Jun. 30, 2017

Stockholders' Equity Note [Abstract]

Stockholders' Equity

During the six month period ended June 30, 2017, the Company:

a)	Issued 8,000,000 shares of common stock to investors (which included both the President and CEO as well as the CFO of the Company) at $0.04 for gross proceeds of $320,000.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

10. Related Party Transactions and Balances

6 Months Ended

Jun. 30, 2017

Related Party Transactions and Balances

Note 10. Related Party Transactions and Balances

During the six month period ended June 30, 2016, the Company:

d)	Recognized $271,850 in share-based compensation associated with stock options granted to key management personnel.

During the six months ended June 30, 2017, the Company:

d)	Recognized $198,274 in share-based compensation associated with stock options granted to key management personnel.

As at June 30, 2017 and December 31, 2016, the following amounts are due to related parties:

		June 30,2017		December 31, 2016
Clarence Smith (CEO)	Accounts payable and accrued liabilities	$	-	$	81

Amounts included in accounts payable and accrued liabilities are non-interest bearing, unsecured and repayable on demand.

XML 28 R17.htm IDEA: XBRL DOCUMENT

11. Commitments and Contingency

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingency

As at June 30, 2017, the Company has the following commitments:

g)	Entered into a Material Transfer Agreement effective March 31, 2017 with Proactive Immune Sciences Corporation (“Proactive”) for a term of 1 year. The Company will furnish AAGP™ at no cost to Proactive so that they may test and evaluate AAGP™ for possible use in Immune Cell Banking.

XML 29 R18.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K, filed February 21, 2017, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Use of Estimates	Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.
Cash	Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.
Fair Value of Financial Instruments	Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Level 1 inputs are used to measure cash. At June 30, 2017 there were no other assets or liabilities subject to additional disclosure.
Income Taxes	The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.
Intangible Assets - Patent and Patent Application Costs	The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred. As at June 30, 2017, the Company does not hold any intangible assets with indefinite lives. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents, whereas no amortization has been recognized on the patent application costs as at June 30, 2017.
Research and Development Costs	Research and development costs are expensed as incurred.
Loss per Share and Potentially Dilutive Securities	Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 44,100,000 stock options (June 30, 2016 – 28,600,000), and 6,500,000 warrants (June 30, 2016 – 6,500,000) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.
Share-Based Compensation	The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model. The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance. The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 “Stock-Based Transactions with Nonemployees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.
Common stock	Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.
Related Party Transactions	A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.
Recent Accounting Pronouncements	In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance did not have a material impact on the Company’s financial statements. Accounting Standards Update 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy was effective for periods ending after December 16, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements. Accounting Standards Update 2016-09 – Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect for periods ending after December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The adoption of this guidance did not have a material impact on the Company’s financial statements. Accounting Standards Update 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements. Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements.

XML 30 R19.htm IDEA: XBRL DOCUMENT

3. Prepaid Expenses and Deposits (Tables)

6 Months Ended

Jun. 30, 2017

Prepaid Expenses And Deposits Tables

Prepaid expenses and deposits

The following summarizes the Company’s prepaid expenses and deposits outstanding as at June 30, 2017 and December 31, 2016:

	June 30, 2017		December 31, 2016

Deposit on research agreement (Note 11(c))	$	134,370	$	54,770
Other prepaid expenses		8,130		15,614

	$	142,500	$	70,384

XML 31 R20.htm IDEA: XBRL DOCUMENT

4. Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible asset transactions

Intangible asset transactions are summarized as follows:

	Patent Rights		Patent Application Rights		Total
Cost
Balance, December 31, 2015	$	30,000	$	41,760	$	71,760
Additions		-		33,421		33,421
Balance, December 31, 2016	$	30,000	$	75,181	$	105,181
Additions		-		51,992		51,992
Balance, June 30, 2017	$	30,000	$	127,173	$	157,173

Accumulated amortization
Balance, December 31, 2015	$	1,500	$	-	$	1,500
Amortization		3,000		-		3,000
Balance, December 31, 2016	$	4,500	$	-	$	4,500
Amortization		1,500		-		1,500
Balance, June 30, 2017	$	6,000	$	-	$	6,000

Net carrying amounts
December 31, 2016	$	25,500	$	75,181	$	100,681
June 30, 2017	$	24,000	$	127,173	$	151,173

XML 32 R21.htm IDEA: XBRL DOCUMENT

6. Common Shares Issued for Services (Tables)

6 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock Incentive Plan, Issuances

2017	Number of Shares		Value per Share		Total

January - June 2017		-	$	-	$	-
		-			$	-

2016	Number of Shares		Value per Share		Total

March 2016		100,000	$	0.07	$	7,000
		100,000			$	7,000

XML 33 R22.htm IDEA: XBRL DOCUMENT

7. Stock Options (Tables)

6 Months Ended

Jun. 30, 2017

Stock Options

Schedule of Share-based Compensation, Stock Options, Activity

	Number of Stock Options			Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Life
				$		$		(Years)
Outstanding, December 31, 2016		28,900,000			0.06		0.04
Options granted		16,200,000			0.05		0.06
Options expired		(1,000,000	)		0.10		0.03
Outstanding, June 30, 2017		44,100,000			0.06		0.05	2.72

Schedule of valuation assumptions for options

	June 30, 2017			June 30, 2016
Risk-free interest rate		1.05	%		0.56	%
Dividend yield		0.00	%		0.00	%
Expected stock price volatility		125.00	%		125.00	%
Expected forfeiture rate		0.00	%		0.00	%
Expected life	3.46 years			3.94 years

Schedule of options by exercise price

Expiry date	Exercise Price		Number of Options Outstanding		Number of Options Exercisable
					$
February 25, 2020		0.04		2,000,000		-
February 24, 2018		0.05		1,000,000		1,000,000
February 25, 2020		0.04		4,000,000		4,000,000
February 28, 2020		0.04		5,000,000		5,000,000
June 30, 2018		0.10		600,000		600,000
December 31, 2019		0.08		15,000,000		15,000,000
October 05, 2018		0.08		300,000		300,000
December 31, 2020		0.05		16,200,000		8,100,000
				44,100,000		34,000,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

8. Warrants (Tables)

6 Months Ended

Jun. 30, 2017

Warrants

Schedule of Warrant Activity

Number of Warrants

Weighted

Average Exercise

Price

Balance, December 31, 2016 and June 30, 2017

6,500,000

0.11

Schedule of Stockholders' Equity Note, Warrants or Rights

Number of Warrants		Exercise Price ($)		Expiry Date
	500,000		0.25	November 8, 2018
	6,000,000		0.10	April 22, 2020
	6,500,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 35 R24.htm IDEA: XBRL DOCUMENT

10. Related Party Transactions and Balances (Tables)

6 Months Ended

Jun. 30, 2017

Schedule of related party transactions

		June 30,2017		December 31, 2016
Clarence Smith (CEO)	Accounts payable and accrued liabilities	$	-	$	81

XML 36 R25.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies (Details Narrative) - shares	3 Months Ended	6 Months Ended
	Mar. 31, 2016	Jun. 30, 2017
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share	6,500,000	6,500,000
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share	28,600,000	44,100,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

3. Prepaid Expenses and Deposits (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Prepaid Expenses And Deposits Details
Deposit on research agreement (Note 11(c))	$ 134,370	$ 54,770
Other prepaid expenses	8,130	15,614
Prepaid expenses and deposits	$ 142,500	$ 70,384

XML 38 R27.htm IDEA: XBRL DOCUMENT

4. Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
4. Intangible Assets (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Beginning balance			$ 100,681
Amortization	$ 750	$ 750	1,500	$ 1,500
Ending balance	151,173		151,173		$ 100,681
Patent Rights [Member] \| Cost [Member]
Beginning balance			30,000
Additions					0
Ending balance	30,000		30,000		30,000
Patent Rights [Member] \| Accumulated Amortization [Member]
Beginning balance			4,500
Amortization			1,500		3,000
Ending balance	6,000		6,000		4,500
Patent Rights [Member] \| Net Carrying Amount [Member]
Beginning balance			25,500
Ending balance	24,000		24,000		25,500
Patent Application Rights [Member] \| Cost [Member]
Beginning balance			75,181
Additions			51,992		33,421
Ending balance	127,173		127,173		75,181
Patent Application Rights [Member] \| Accumulated Amortization [Member]
Beginning balance			0
Amortization			0		0
Ending balance	0		0		0
Patent Application Rights [Member] \| Net Carrying Amount [Member]
Beginning balance			75,181
Ending balance	127,173		127,173		75,181
Total [Member] \| Cost [Member]
Beginning balance			105,181	71,760	71,760
Additions			51,992		33,421
Ending balance	157,173		157,173		105,181
Total [Member] \| Accumulated Amortization [Member]
Beginning balance			4,500	$ 1,500	1,500
Amortization			1,500		3,000
Ending balance	6,000		6,000		4,500
Total [Member] \| Net Carrying Amount [Member]
Beginning balance			100,681
Ending balance	$ 151,173		$ 151,173		$ 100,681

XML 39 R28.htm IDEA: XBRL DOCUMENT

4. Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
4. Intangible Assets (Details Narrative) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization - intangible assets	$ 750	$ 750	$ 1,500	$ 1,500

XML 40 R29.htm IDEA: XBRL DOCUMENT

5. Credit Facility (Details Narrative) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Line of credit	$ 250,000	$ 250,000

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

XML 41 R30.htm IDEA: XBRL DOCUMENT

6. Common Shares Issued for Services (Details) - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2016	Jun. 30, 2017
Number of Shares	7,000	0
Total	$ 7,000	$ 0
March 2016
Number of Shares	100,000
Value per Share	$ .07
Total	$ 7,000
January - March 2017
Number of Shares	0
Value per Share	$ 0
Total	$ 0

XML 42 R31.htm IDEA: XBRL DOCUMENT

7. Stock Options (Details) - $ / shares	6 Months Ended
7. Stock Options (Details) - $ / shares	Jun. 30, 2017	Jun. 30, 2016
Outstanding, ending	44,100,000
Weighted Average Exercise Price ending	$ 0.11
Weighted Average Fair Value, granted	$ .06	$ 0.05
Stock options
Outstanding, beginning	28,900,000
Options granted	16,200,000
Options expired	(1,000,000)
Outstanding, ending	44,100,000
Weighted Average Exercise Price beginning	$ 0.06
Weighted Average Exercise Price, granted	0.05
Weighted Average Exercise Price, expired	0.10
Weighted Average Exercise Price ending	0.06
Weighted Average Fair Value, beginning	0.04
Weighted Average Fair Value, granted	0.06
Weighted Average Fair Value, expired	0.03
Weighted Average Fair Value, ending	$ 0.05
Weighted Average Remaining Life (Years)	2 years 8 months 19 days

XML 43 R32.htm IDEA: XBRL DOCUMENT

7. Stock Options (Details 1) - Stock options	6 Months Ended
7. Stock Options (Details 1) - Stock options	Jun. 30, 2017	Jun. 30, 2016
Risk-free interest rate	1.05%	0.56%
Dividend yield	0.00%	0.00%
Expected stock price volatility	125.00%	125.00%
Expected forfeiture rate	0.00%	0.00%
Expected life	3 years 5 months 8 days	3 years 11 months 12 days

XML 44 R33.htm IDEA: XBRL DOCUMENT

7. Stock Options (Details 2)	Jun. 30, 2017 $ / shares shares
Exercise Price \| $ / shares	$ 0.11
Number of Options Outstanding	44,100,000
Number of options exercisable	34,000,000
February 25, 2020 One
Exercise Price \| $ / shares	$ 0.04
Number of Options Outstanding	2,000,000
Number of options exercisable
February 24, 2018
Exercise Price \| $ / shares	$ 0.05
Number of Options Outstanding	1,000,000
Number of options exercisable	1,000,000
February 25, 2020
Exercise Price \| $ / shares	$ 0.04
Number of Options Outstanding	4,000,000
Number of options exercisable	4,000,000
February 28, 2020
Exercise Price \| $ / shares	$ 0.04
Number of Options Outstanding	5,000,000
Number of options exercisable	5,000,000
June 30, 2018
Exercise Price \| $ / shares	$ 0.10
Number of Options Outstanding	600,000
Number of options exercisable	600,000
December 31, 2019
Exercise Price \| $ / shares	$ 0.08
Number of Options Outstanding	15,000,000
Number of options exercisable	15,000,000
October 05, 2018
Exercise Price \| $ / shares	$ 0.08
Number of Options Outstanding	300,000
Number of options exercisable	300,000
December 31, 2020
Exercise Price \| $ / shares	$ 0.05
Number of Options Outstanding	16,200,000
Number of options exercisable	8,100,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

7. Stock Options (Details Narrative) - USD ($)	6 Months Ended
7. Stock Options (Details Narrative) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Aggregate intrinsic value	$ 674,000		$ 110,000
Weighted average fair value of stock options granted per share	$ .06	$ 0.05
Options
Common stock granted	16,200,000
Common Stock
Common stock granted	0

XML 46 R35.htm IDEA: XBRL DOCUMENT

8. Warrants (Details)	Jun. 30, 2017 $ / shares shares
Notes to Financial Statements [Abstract]
Warrant outstanding, ending \| shares	6,500,000
Warrant weighted average exercise price \| $ / shares	$ 0.11

XML 47 R36.htm IDEA: XBRL DOCUMENT

8. Warrants (Details 1)	6 Months Ended
8. Warrants (Details 1)	Jun. 30, 2017 $ / shares shares
Number of Warrants	6,500,000
Warrant One
Number of Warrants	500,000
Warrant Exercise Price \| $ / shares	$ 0.25
Expiry Date	November 8, 2018
Warrant Two
Number of Warrants	6,000,000
Warrant Exercise Price \| $ / shares	$ 0.10
Expiry Date	April 22, 2020

XML 48 R37.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (Details Narrative) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Common Stock, Par Value Per Share	$ 0.0000053	$ 0.0000053
Common Stock, Shares Authorized	400,000,000	400,000,000
Dividends declared	$ 0	$ 0

XML 49 R38.htm IDEA: XBRL DOCUMENT

10. Related Party Transactions and Balances (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accounts payable and accrued liabilities	$ 5,369	$ 45,295
Clarence Smith (CEO)
Accounts payable and accrued liabilities		$ 81

XML 50 R39.htm IDEA: XBRL DOCUMENT

10. Related Party Transactions and Balances (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Related Party Transactions [Abstract]
Payment to CFO	$ 36,000	$ 36,000

XML 51 R40.htm IDEA: XBRL DOCUMENT

11. Commitments and Contingency (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Commitments And Contingency Details Narrative
Additional Paid In Capital	$ 29,852,293		$ 29,115,795
prepaid expenses and deposits	134,370	$ 154,595
prepaid expenses	$ 8,130

EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 53 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 76 125 1 false 25 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://protokinetix.com/taxonomy/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS (Unaudited) Sheet http://protokinetix.com/role/BalanceSheets BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://protokinetix.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATIONS (Unaudited) Sheet http://protokinetix.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://protokinetix.com/role/StatementOfStockholdersEquity STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://protokinetix.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - 1. Basis of Presentation - Going Concern Uncertainties Sheet http://protokinetix.com/role/BasisOfPresentation-GoingConcernUncertainties 1. Basis of Presentation - Going Concern Uncertainties Notes 7 false false R8.htm 00000008 - Disclosure - 2. Summary of Significant Accounting Policies Sheet http://protokinetix.com/role/SummaryOfSignificantAccountingPolicies 2. Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - 3. Prepaid Expenses and Deposits Sheet http://protokinetix.com/role/PrepaidExpensesAndDeposits 3. Prepaid Expenses and Deposits Notes 9 false false R10.htm 00000010 - Disclosure - 4. Intangible Assets Sheet http://protokinetix.com/role/IntangibleAssets 4. Intangible Assets Notes 10 false false R11.htm 00000011 - Disclosure - 5. Credit Facility Sheet http://protokinetix.com/role/CreditFacility 5. Credit Facility Notes 11 false false R12.htm 00000012 - Disclosure - 6. Common Shares Issued for Services Sheet http://protokinetix.com/role/CommonSharesIssuedForServices 6. Common Shares Issued for Services Notes 12 false false R13.htm 00000013 - Disclosure - 7. Stock Options Sheet http://protokinetix.com/role/StockOptions 7. Stock Options Notes 13 false false R14.htm 00000014 - Disclosure - 8. Warrants Sheet http://protokinetix.com/role/Warrants 8. Warrants Notes 14 false false R15.htm 00000015 - Disclosure - 9. Stockholders' Equity Sheet http://protokinetix.com/role/StockholdersEquity 9. Stockholders' Equity Notes 15 false false R16.htm 00000016 - Disclosure - 10. Related Party Transactions and Balances Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalances 10. Related Party Transactions and Balances Notes 16 false false R17.htm 00000017 - Disclosure - 11. Commitments and Contingency Sheet http://protokinetix.com/role/CommitmentsAndContingency 11. Commitments and Contingency Notes 17 false false R18.htm 00000018 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) Sheet http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies 2. Summary of Significant Accounting Policies (Policies) Policies http://protokinetix.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - 3. Prepaid Expenses and Deposits (Tables) Sheet http://protokinetix.com/role/PrepaidExpensesAndDepositsTables 3. Prepaid Expenses and Deposits (Tables) Tables http://protokinetix.com/role/PrepaidExpensesAndDeposits 19 false false R20.htm 00000020 - Disclosure - 4. Intangible Assets (Tables) Sheet http://protokinetix.com/role/IntangibleAssetsTables 4. Intangible Assets (Tables) Tables http://protokinetix.com/role/IntangibleAssets 20 false false R21.htm 00000021 - Disclosure - 6. Common Shares Issued for Services (Tables) Sheet http://protokinetix.com/role/CommonSharesIssuedForServicesTables 6. Common Shares Issued for Services (Tables) Tables http://protokinetix.com/role/CommonSharesIssuedForServices 21 false false R22.htm 00000022 - Disclosure - 7. Stock Options (Tables) Sheet http://protokinetix.com/role/StockOptionsTables 7. Stock Options (Tables) Tables http://protokinetix.com/role/StockOptions 22 false false R23.htm 00000023 - Disclosure - 8. Warrants (Tables) Sheet http://protokinetix.com/role/WarrantsTables 8. Warrants (Tables) Tables http://protokinetix.com/role/Warrants 23 false false R24.htm 00000024 - Disclosure - 10. Related Party Transactions and Balances (Tables) Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesTables 10. Related Party Transactions and Balances (Tables) Tables http://protokinetix.com/role/RelatedPartyTransactionsAndBalances 24 false false R25.htm 00000025 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) Sheet http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative 2. Summary of Significant Accounting Policies (Details Narrative) Details http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies 25 false false R26.htm 00000026 - Disclosure - 3. Prepaid Expenses and Deposits (Details) Sheet http://protokinetix.com/role/PrepaidExpensesAndDepositsDetails 3. Prepaid Expenses and Deposits (Details) Details http://protokinetix.com/role/PrepaidExpensesAndDepositsTables 26 false false R27.htm 00000027 - Disclosure - 4. Intangible Assets (Details) Sheet http://protokinetix.com/role/IntangibleAssetsDetails 4. Intangible Assets (Details) Details http://protokinetix.com/role/IntangibleAssetsTables 27 false false R28.htm 00000028 - Disclosure - 4. Intangible Assets (Details Narrative) Sheet http://protokinetix.com/role/IntangibleAssetsDetailsNarrative 4. Intangible Assets (Details Narrative) Details http://protokinetix.com/role/IntangibleAssetsTables 28 false false R29.htm 00000029 - Disclosure - 5. Credit Facility (Details Narrative) Sheet http://protokinetix.com/role/CreditFacilityDetailsNarrative 5. Credit Facility (Details Narrative) Details http://protokinetix.com/role/CreditFacility 29 false false R30.htm 00000030 - Disclosure - 6. Common Shares Issued for Services (Details) Sheet http://protokinetix.com/role/CommonSharesIssuedForServicesDetails 6. Common Shares Issued for Services (Details) Details http://protokinetix.com/role/CommonSharesIssuedForServicesTables 30 false false R31.htm 00000031 - Disclosure - 7. Stock Options (Details) Sheet http://protokinetix.com/role/StockOptionsDetails 7. Stock Options (Details) Details http://protokinetix.com/role/StockOptionsTables 31 false false R32.htm 00000032 - Disclosure - 7. Stock Options (Details 1) Sheet http://protokinetix.com/role/StockOptionsDetails1 7. Stock Options (Details 1) Details http://protokinetix.com/role/StockOptionsTables 32 false false R33.htm 00000033 - Disclosure - 7. Stock Options (Details 2) Sheet http://protokinetix.com/role/StockOptionsDetails2 7. Stock Options (Details 2) Details http://protokinetix.com/role/StockOptionsTables 33 false false R34.htm 00000034 - Disclosure - 7. Stock Options (Details Narrative) Sheet http://protokinetix.com/role/StockOptionsDetailsNarrative 7. Stock Options (Details Narrative) Details http://protokinetix.com/role/StockOptionsTables 34 false false R35.htm 00000035 - Disclosure - 8. Warrants (Details) Sheet http://protokinetix.com/role/WarrantsDetails 8. Warrants (Details) Details http://protokinetix.com/role/WarrantsTables 35 false false R36.htm 00000036 - Disclosure - 8. Warrants (Details 1) Sheet http://protokinetix.com/role/WarrantsDetails1 8. Warrants (Details 1) Details http://protokinetix.com/role/WarrantsTables 36 false false R37.htm 00000037 - Disclosure - 9. Stockholders' Equity (Details Narrative) Sheet http://protokinetix.com/role/StockholdersEquityDetailsNarrative 9. Stockholders' Equity (Details Narrative) Details http://protokinetix.com/role/StockholdersEquity 37 false false R38.htm 00000038 - Disclosure - 10. Related Party Transactions and Balances (Details) Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetails 10. Related Party Transactions and Balances (Details) Details http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesTables 38 false false R39.htm 00000039 - Disclosure - 10. Related Party Transactions and Balances (Details Narrative) Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative 10. Related Party Transactions and Balances (Details Narrative) Details http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesTables 39 false false R40.htm 00000040 - Disclosure - 11. Commitments and Contingency (Details Narrative) Sheet http://protokinetix.com/role/CommitmentsAndContingencyDetailsNarrative 11. Commitments and Contingency (Details Narrative) Details http://protokinetix.com/role/CommitmentsAndContingency 40 false false All Reports Book All Reports pktx-20170630.xml pktx-20170630.xsd pktx-20170630_cal.xml pktx-20170630_def.xml pktx-20170630_lab.xml pktx-20170630_pre.xml true true ZIP 58 0001079973-17-000456-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-17-000456-xbrl.zip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end